



(51) International Patent Classification:

C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2020/053114

(22) International Filing Date:

28 September 2020 (28.09.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/906,918

27 September 2019 (27.09.2019) US

(71) Applicant: **AGENUS INC.** [US/US]; 3 Forbes Road, Lexington, Massachusetts 02421 (US).

(72) Inventors: **CHAND, Dhan Sidhartha**; c/o Agenus Inc., 3 Forbes Road, Lexington, Massachusetts 02421 (US). **JAWAD, Zahra**; c/o Agenus Inc., 3 Forbes Road, Lexington, Massachusetts 02421 (US). **ILKOW, Veronica Franciszka**; c/o Agenus Inc., 3 Forbes Road, Lexington, Massachusetts 02421 (US).


(74) Agent: **WILKINS, Andrew**; Dechert LLP, One International Place, 40th Floor, 100 Oliver Street, Boston, MA 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: HETERODIMERIC PROTEINS

Figure 1



(57) **Abstract:** Provided herein are heterodimeric proteins (e.g., multispecific antibodies) that exhibit enhanced binding to human Fc gamma receptor IIIA (FcγRIIIA) relative to naturally occurring antibodies and retain good manufacturability. Such heterodimeric proteins are particular useful as multispecific binding proteins (e.g., multispecific antibodies). Also provided are pharmaceutical compositions comprising these heterodimeric proteins, nucleic acids encoding these heterodimeric proteins, and expression vectors and host cells for making these heterodimeric proteins.



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

HETERODIMERIC PROTEINS

RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 62/906,918, filed September 27, 2019, which is incorporated by reference herein in its entirety.

1. FIELD

[0002] The instant disclosure relates to heterodimeric proteins (e.g., multispecific antibodies) and methods of making the same.

2. BACKGROUND

[0003] Multispecific binding molecules (e.g., multispecific antibodies) comprising two or more binding specificities hold great promise as therapeutics because of the ability of these molecules to modulate the activity of multiple targets *in vivo*. One common method for producing multispecific antibodies is to heterodimerize the heavy chains of two different antibodies. To facilitate this heterodimerization, the CH3 domains of the two antibodies are engineered to contain complementary sets of mutations that result in a preference for heavy chain heterodimerization relative to homodimerization (see e.g., Ridgway J.B. et al., 1996, Protein Eng., 9:617-621; and U.S. Patent No. 9,409,989, each of which is herein incorporated by reference in its entirety).

[0004] In certain instances, it is desirable to enhance the binding of the Fc region of a multispecific antibody to human Fc gamma receptor IIIA (FcγRIIIA) relative to that of the Fc region of a corresponding naturally occurring antibody. One method of achieving this enhanced FcγRIIIA binding is to engineer the Fc region of the multispecific antibody to comprise specific amino acid mutations at amino acid positions 239, 330, and 332 of the Fc region, according to the EU index (see e.g., Lazar, G.A. et al., 2006, PNAS, 103(11):4005-4010). However, Applicant has discovered that combining these Fc mutations with heterodimerization-enhancing Fc mutations at amino acid positions 366, 368 and 407, according to the EU index, can negatively impact the manufacturability of multispecific antibodies comprising these mutations.

[0005] Accordingly, there is a need in the art for improved multispecific antibodies that exhibit enhanced binding to FcγRIIIA, while retaining good manufacturability.

3. SUMMARY

[0006] The instant disclosure provides heterodimeric proteins (e.g., multispecific antibodies) that exhibit enhanced binding to FcγRIIIA relative to a corresponding naturally occurring antibody and exhibit good manufacturability. The heterodimeric proteins generally comprise a first Fc polypeptide comprising aspartate, glutamate, and tryptophan at amino acid positions 239, 332, and 366, respectively; and a second Fc polypeptide comprising aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but not comprising glutamate at amino acid position 332, wherein the amino acid positions are numbered according to the EU index. In certain embodiments, the heterodimeric proteins comprise a first Fc polypeptide comprising aspartate, leucine, glutamate, and tryptophan at amino acid positions 239, 330, 332, and 366, respectively; and a second Fc polypeptide comprising aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but not comprising leucine and glutamate at amino acid positions 330 and 332, respectively, wherein the amino acid positions are numbered according to the EU index. Such heterodimeric proteins are particularly useful as multispecific binding proteins (e.g., multispecific antibodies). Also provided are pharmaceutical compositions comprising these heterodimeric proteins, nucleic acids encoding these heterodimeric proteins, and expression vectors and host cells for making these heterodimeric proteins. Without wishing to be bound by theory, Applicant believes that the second Fc polypeptide of the heterodimeric proteins disclosed herein has improved thermal stability relative to a corresponding Fc polypeptide comprising mutations at amino acid positions 239, 330, 332, 366, 368, and 407, numbered according to the EU index.

[0007] Accordingly, in one aspect the instant disclosure provides heterodimeric proteins.

[0008] In certain embodiments, the heterodimeric protein comprises a first Fc polypeptide and a second Fc polypeptide, wherein: the first Fc polypeptide comprises aspartate, glutamate, and tryptophan at amino acid positions 239, 332, and 366, respectively; and the second Fc polypeptide comprises aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but does not comprise glutamate at amino acid position 332, wherein the amino acid positions are numbered according to the EU index. In certain embodiments, the first Fc polypeptide further comprises leucine at amino acid position 330, wherein the amino acid positions are numbered according to the EU index. In certain embodiments, the second Fc polypeptide does not comprise leucine at amino acid position 330, wherein the amino acid positions are numbered

according to the EU index.

[0009] In certain embodiments, the first Fc polypeptide comprises a first antigen-binding moiety and/or the second Fc polypeptide comprises a second antigen-binding moiety. In certain embodiments, the first and/or second antigen-binding moiety comprises an antibody variable domain, an extracellular domain of a cell surface receptor, a soluble T cell receptor (e.g., a T cell receptor lacking endogenous transmembrane and cytoplasmic regions), or a ligand. In certain embodiments, the first and/or second antigen-binding moiety comprises a VH, a VL, a VHH, a VH/VL pair, an scFv, a diabody, and/or a Fab. In certain embodiments, the cell surface receptor is a tumor necrosis factor superfamily receptor, a vascular endothelial growth factor receptor, or a transforming growth factor receptor. In certain embodiments, the soluble T cell receptor comprises an extracellular, antigen-binding portion of a T cell receptor stabilized by one or more engineered disulphide bonds. In certain embodiments, the soluble T cell receptor comprises a single chain T cell receptor comprising variable regions of a T cell receptor linked together by a flexible linker (e.g., a peptide linker). In certain embodiments, the ligand is a hormone or growth factor. In certain embodiments, the first and second antigen-binding moieties specifically bind to the same or different target molecules.

[0010] In certain embodiments, the first and/or second Fc polypeptide comprises a CH1 domain, hinge region, CH2 domain and/or CH3 domain of human IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂. In certain embodiments, the first and/or second Fc polypeptide comprises an antibody heavy chain. In certain embodiments, the antibody heavy chain lacks a CH1 domain and/or a portion of a hinge region. In certain embodiments, the antibody heavy chain is a full-length antibody heavy chain. In certain embodiments, the antibody heavy chain is a human IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂ heavy chain.

[0011] In certain embodiments, the first and/or second Fc polypeptide further comprises an antibody light chain. In certain embodiments, the antibody light chain is a human kappa or lambda light chain.

[0012] In certain embodiments, the first Fc polypeptide comprises a first half-antibody comprising a first antibody heavy chain and a first antibody light chain; and/or the second Fc polypeptide comprises a second half-antibody comprising a second antibody heavy chain and a second antibody light chain. In certain embodiments, the first Fc polypeptide comprises a first half-antibody comprising a first antibody heavy chain and a first antibody light chain; and the

second Fc polypeptide comprises a second half-antibody comprising a second antibody heavy chain and a second antibody light chain. In certain embodiments, the first and second half-antibodies bind to different target molecules or to different regions of the same target molecule.

[0013] In certain embodiments, the first Fc polypeptide comprises an amino acid sequence that is at least 75% identical (optionally at least 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical) to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, 6-7, 10-11, 24-27, 48-51, and 62-65; and/or the second Fc polypeptide comprises an amino acid sequence that is at least 75% identical (optionally at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical) to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, 5, 12-13, 36-37, 60-61, and 66-67.

[0014] In certain embodiments, the first Fc polypeptide comprises an amino acid sequence that is at least 75% identical (optionally at least 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical) to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, 6-7, 10-11, 24-27, 48-51, and 62-65; and the second Fc polypeptide comprises an amino acid sequence that is at least 75% identical (optionally at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical) to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, 5, 12-13, 36-37, 60-61, and 66-67.

[0015] In certain embodiments, the first Fc polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3, 6-7, 10-11, 24-27, 48-51, and 62-65. In certain embodiments, the second Fc polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3, 5, 12-13, 36-37, 60-61, and 66-67.

[0016] In certain embodiments, the first Fc polypeptide and second Fc polypeptide comprise amino acid sequences that are at least 75% identical (e.g., at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical) to the amino acid sequences of SEQ ID NOs: 24 and 36; 24 and 37; 25 and 36; 25 and 37; 26 and 36; 26 and 37; 27 and 36; 27 and 37; 48 and 60; 48 and 61; 49 and 60; 49 and 61; 50 and 60; 50 and 61; 51 and 60; 51 and 61; 62 and 66; 62 and 67; 63 and 66; 63 and 67; 64 and 66; 64 and 67; 65 and 66; or 65 and 67, respectively. In certain embodiments, the first Fc polypeptide and second Fc polypeptide comprise the amino acid sequences of SEQ ID NOs: 24 and 36; 24 and 37; 25 and 36;

25 and 37; 26 and 36; 26 and 37; 27 and 36; 27 and 37; 48 and 60; 48 and 61; 49 and 60; 49 and 61; 50 and 60; 50 and 61; 51 and 60; 51 and 61; 62 and 66; 62 and 67; 63 and 66; 63 and 67; 64 and 66; 64 and 67; 65 and 66; or 65 and 67, respectively.

[0017] In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 51 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 61. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 50 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 60. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 51 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 60. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 50 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 61. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 49 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 61. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 48 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 60. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 49 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 60. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 48 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 61. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 65 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 67. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 64 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 66. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 65 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 66. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 64 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 67. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 63 and the second Fc polypeptide comprises the amino acid

sequence set forth in SEQ ID NO: 67. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 62 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 66. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 63 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 66. In certain embodiments, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 62 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 67. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 27 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 37. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 26 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 36. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 27 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 36. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 26 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 37. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 25 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 37. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 24 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 36. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 25 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 36. In certain embodiments, the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 24 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 37.

[0018] In another aspect the instant disclosure provides pharmaceutical compositions comprising the heterodimeric proteins disclosed herein. In certain embodiments, the pharmaceutical composition comprises a heterodimeric protein disclosed herein and a pharmaceutically acceptable carrier or excipient.

[0019] In another aspect the instant disclosure provides isolated polynucleotides encoding the Fc polypeptides disclosed herein, vectors comprising the polynucleotides, and recombinant host

cells comprising the polynucleotides, vectors, and Fc polypeptides disclosed herein. In certain embodiments, the isolated polynucleotide encodes the first and second Fc polypeptide of any of any of the heterodimeric proteins disclosed herein. In certain embodiments, the vector comprises a polynucleotide encoding the first and second Fc polypeptide of any of any of the heterodimeric proteins disclosed herein.

[0020] In certain embodiments, the recombinant host cell comprises:

- a) a polynucleotide encoding the first and second Fc polypeptide of any of any of the heterodimeric proteins disclosed herein;
- b) a vector comprising a polynucleotide encoding the first and second Fc polypeptide of any of any of the heterodimeric proteins disclosed herein;
- c) a first polynucleotide encoding the first Fc polypeptide of any of the heterodimeric proteins disclosed herein, and a second polynucleotide encoding the second Fc polypeptide of any of the heterodimeric proteins disclosed herein;
- d) a first vector comprising a first polynucleotide encoding the first Fc polypeptide of any of the heterodimeric proteins disclosed herein, and a second vector comprising a second polynucleotide encoding the second Fc polypeptide of any of the heterodimeric proteins disclosed herein;
- e) a first polynucleotide encoding a first antibody heavy chain of a first Fc polypeptide of a heterodimeric protein disclosed herein, and a second polynucleotide encoding the second antibody heavy chain of a second Fc polypeptide of a heterodimeric protein disclosed herein, and optionally a third polynucleotide encoding a first antibody light chain of the first Fc polypeptide, and/or a fourth polynucleotide encoding a second antibody light chain of the second Fc polypeptide;
wherein the first Fc polypeptide comprises a first half-antibody comprising a first antibody heavy chain and a first antibody light chain; and the second Fc polypeptide comprises a second half-antibody comprising a second antibody heavy chain and a second antibody light chain; or
- f) a first vector comprising a first polynucleotide encoding the first antibody heavy chain of a first Fc polypeptide of a heterodimeric protein disclosed herein, and a second vector comprising a second polynucleotide encoding a second antibody

heavy chain of a second Fc polypeptide of a heterodimeric protein disclosed herein, and optionally a third vector comprising a third polynucleotide encoding the first antibody light chain of the first Fc polypeptide, and/or a fourth vector comprising a fourth polynucleotide encoding the second antibody light chain of the second Fc polypeptide,

wherein the first Fc polypeptide comprises a first half-antibody comprising a first antibody heavy chain and a first antibody light chain; and the second Fc polypeptide comprises a second half-antibody comprising a second antibody heavy chain and a second antibody light chain.

[0021] In another aspect the instant disclosure provides methods for producing the heterodimeric proteins described herein.

[0022] In certain embodiments, the method comprises expressing in a cell a first polynucleotide encoding the first Fc polypeptide of any of the heterodimeric proteins disclosed herein; and a second polynucleotide encoding the second Fc polypeptide of any of the heterodimeric proteins disclosed herein, under conditions whereby the heterodimeric protein is produced.

[0023] In certain embodiments, the method comprises expressing in a cell:

- a) a first polynucleotide encoding the first antibody heavy chain of a first Fc polypeptide of a heterodimeric protein disclosed herein;
- b) a second polynucleotide encoding the second antibody heavy chain of a second Fc polypeptide of a heterodimeric protein disclosed herein;
- c) a third polynucleotide encoding the first antibody light chain of the first Fc polypeptide; and
- d) a fourth polynucleotide encoding the second antibody light chain of the second Fc polypeptide,

under conditions whereby the heterodimeric protein is produced,

wherein the first Fc polypeptide comprises a first half-antibody comprising a first antibody heavy chain and a first antibody light chain; and the second Fc polypeptide comprises a second half-antibody comprising a second antibody heavy chain and a second antibody light chain.

[0024] In certain embodiments, the method comprises:

- a) expressing in a first cell a first polynucleotide encoding the first Fc polypeptide of any of the heterodimeric proteins disclosed herein, under conditions whereby the first Fc polypeptide is produced;
- b) expressing in a second cell a second polynucleotide encoding the second Fc polypeptide of any of the heterodimeric proteins disclosed herein, under conditions whereby the second Fc polypeptide is produced; and
- c) contacting the first and the second Fc polypeptides produced in steps (a) and (b), under conditions whereby the first Fc polypeptide and the second Fc polypeptide heterodimerize to produce the heterodimeric protein.

[0025] In certain embodiments, the method comprises:

- a) expressing in a first cell a first polynucleotide encoding the first antibody heavy chain and second polynucleotide encoding the first antibody light chain of a first Fc polypeptide of a heterodimeric protein disclosed herein, under conditions whereby the first Fc polypeptide is produced;
- b) expressing in a second cell a third polynucleotide encoding the second antibody heavy chain and a fourth polynucleotide encoding the second antibody light chain a second Fc polypeptide of a heterodimeric protein disclosed herein, under conditions whereby the second Fc polypeptide is produced; and
- c) contacting the first and the second Fc polypeptides produced in steps (a) and (b), under conditions whereby the first Fc polypeptide and the second Fc polypeptide heterodimerize to produce the heterodimeric protein, wherein the first Fc polypeptide comprises a first half-antibody comprising a first antibody heavy chain and a first antibody light chain; and the second Fc polypeptide comprises a second half-antibody comprising a second antibody heavy chain and a second antibody light chain.

[0026] In certain embodiments, the method comprises contacting the first Fc polypeptide and the second Fc polypeptide of the heterodimeric protein of any of the heterodimeric proteins disclosed herein under conditions whereby the first Fc polypeptide and the second Fc polypeptide heterodimerize to produce the heterodimeric protein.

4. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] **Figure 1** is a graph showing expression levels of a subset of the Fc polypeptides described in Table 3.

[0028] **Figures 2A and 2B** are graphs showing the thermal stability of heterodimeric proteins BA111, BA112, BA113, and BA114 (Figure 2A; “anti-Target 1 antibody”) and BA115, BA116, BA117, and BA118 (Figure 2B; “anti-Target 2 antibody”) as determined by measuring thermal unfolding transition.

[0029] **Figure 3** is a graph showing the binding of heterodimeric proteins BA111, BA112, BA113, BA114, BA119, and an IgG₁ isotype control antibody to Jurkat cells engineered to express high levels of cell surface Target 1. In each case, the extent of binding to Jurkat cells, as assessed by median fluorescence intensity (MFI), is plotted against the concentration of the heterodimeric protein (“antibody”) incubated with the cells.

[0030] **Figure 4** is a graph showing the binding of heterodimeric proteins BA115, BA116, BA117, BA118, BA120, and an IgG₁ isotype control antibody to CHO cells engineered to express high levels of cell surface Target 2. In each case, the extent of binding to CHO cells, as assessed by median fluorescence intensity (MFI), is plotted against the concentration of the heterodimeric protein (“antibody”) incubated with the cells.

[0031] **Figure 5** is a graph showing the results of IL-2-luciferase reporter assays measuring the relative amount of T cell activation resulting from Target 1 blockade using the heterodimeric proteins BA111, BA112, BA113, BA114, BA119, or an IgG₁ isotype control antibody. Luciferase expression (measured in average RLU), a surrogate marker for IL-2 gene activation, is plotted against heterodimeric protein (“antibody”) concentration.

[0032] **Figure 6** is a graph showing the results of IL-2-luciferase reporter assays measuring the relative amount of T cell activation resulting from Target 2 blockade using the heterodimeric proteins BA115, BA116, BA117, BA118, BA120, or an IgG₁ isotype control antibody. Luciferase expression (measured in average RLU), a surrogate marker for IL-2 gene activation, is plotted against heterodimeric protein (“antibody”) concentration.

[0033] **Figures 7A-7P** are graphs showing the ability of heterodimeric proteins BA111, BA112, BA113, BA114, BA119, and Reference Homodimeric Protein 2 to induced IL-2 secretion by SEA-stimulated PBMCs in three different donors, Donor 1 (Figures 7A-7D and Figures 7I-7L), Donor 2 (Figures 7E-7H), and Donor 3 (Figures 7M-7P). A homodimeric isotype protein, which

comprises S239D/A330L/I332E mutations (“Fc enhanced”) was used as an isotype control. IL-2 concentration is plotted against heterodimeric protein (“antibody”) concentration.

[0034] **Figures 8A-8X** are graphs showing the ability of BA115, BA116, BA117, BA118, and Reference Homodimeric Protein 1 to induce IL-2 secretion by SEA-stimulated PBMCs in three different donors, Donor 1 (Figures 8A-8D and 8M-8P), Donor 2 (Figures 8I-8L and 8U-8X), and Donor 3 (Figures 8E-8H and 8Q-8T). A homodimeric isotype protein, which comprises S239D/A330L/I332E mutations (“Fc enhanced”) was used as an isotype control. IL-2 concentration is plotted against heterodimeric protein (“antibody”) concentration.

[0035] **Figures 9A and 9B** are a set of graphs showing the binding of heterodimeric proteins BA111, BA112, BA113, and BA114 to CHO cells expressing cell surface human FcγRIIIA V/V (Figure 9A) or CHO cells expressing cell surface human FcγRIIIA F/F (Figure 9B). The level of heterodimeric protein binding to the cells, as assessed by the geometric mean fluorescence intensity (MFI), was plotted against the concentrations of heterodimeric protein (“Ab”) incubated with the cells.

[0036] **Figures 10A and 10B** are a set of graphs showing the binding of heterodimeric protein BA115, BA116, BA117, and BA118 to CHO cells expressing cell surface human FcγRIIIA V/V (Figure 10A) or CHO cells expressing cell surface human FcγRIIIA F/F (Figure 10B). The level of heterodimeric protein binding to the cells, as assessed by the geometric mean fluorescence intensity (MFI), was plotted against the concentrations of heterodimeric protein (“Ab”) incubated with the cells.

[0037] **Figures 11A-11G** are a set of graphs showing binding of anti-target 1 heterodimeric proteins to CHO cells expressing cell surface human FcγRIIIA F/F. The level of heterodimeric protein binding to the cells, as assessed by the geometric mean fluorescence intensity (MFI), was plotted against the concentrations of heterodimeric protein incubated with the cells.

[0038] **Figures 12A-12G** are a set of graphs showing binding of anti-target 2 heterodimeric proteins to CHO cells expressing cell surface human FcγRIIIA F/F. The level of heterodimeric protein binding to the cells, as assessed by the geometric mean fluorescence intensity (MFI), was plotted against the concentrations of heterodimeric protein incubated with the cells.

5. DETAILED DESCRIPTION

[0039] Provided herein are heterodimeric proteins (e.g., multispecific antibodies) that exhibit

enhanced binding to FcγRIIIA relative to a corresponding naturally occurring antibody and exhibit good manufacturability. The heterodimeric proteins generally comprise a first Fc polypeptide comprising aspartate, glutamate, and tryptophan at amino acid positions 239, 332, and 366, respectively; and a second Fc polypeptide comprising aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but not comprising glutamate at amino acid position 332, wherein the amino acid positions are numbered according to the EU index. In certain embodiments, the heterodimeric proteins comprise a first Fc polypeptide comprising aspartate, leucine, glutamate, and tryptophan at amino acid positions 239, 330, 332, and 366, respectively; and a second Fc polypeptide comprising aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but not comprising leucine and glutamate at amino acid positions 330 and 332, respectively, wherein the amino acid positions are numbered according to the EU index. Such heterodimeric proteins are particularly useful as multispecific binding proteins (e.g., multispecific antibodies). Also provided are pharmaceutical compositions comprising these heterodimeric proteins, nucleic acids encoding these heterodimeric proteins, and expression vectors and host cells for making these heterodimeric proteins.

5.1 Definitions

[0040] As used herein, the term “heterodimeric protein” refers to a protein comprising a covalently or non-covalently linked dimer of two non-identical Fc polypeptides.

[0041] As used herein, the term “Fc polypeptide” refers to a polypeptide comprising a CH2 domain and a CH3 domain, wherein the C-terminus of the CH2 domain is linked (directly or indirectly) to the N-terminus of the CH3 domain. The term “Fc polypeptide” includes an antibody heavy chain linked to an antibody light chain by disulphide bonds (e.g., to form a half-antibody).

[0042] As used herein, the term “CH1 domain” refers to the first constant domain of an antibody heavy chain (e.g., amino acid positions 118-215 of human IgG₁, according to the EU index). The term includes naturally occurring CH1 domains and engineered variants of naturally occurring CH1 domains (e.g., CH1 domains comprising one or more amino acid insertions, deletions, substitutions, or modifications relative to a naturally occurring CH1 domain).

[0043] As used herein, the term “CH2 domain” refers to the second constant domain of an antibody heavy chain (e.g., amino acid positions 231-340 of human IgG₁, according to the EU index). The term includes naturally occurring CH2 domains and engineered variants of naturally occurring CH2 domains (e.g., CH2 domains comprising one or more amino acid insertions,

deletions, substitutions, or modifications relative to a naturally occurring CH2 domain).

[0044] As used herein, the term “CH3 domain” refers to the third constant domain of an antibody heavy chain (e.g., amino acid positions 341-447 of human IgG₁, according to the EU index). The term includes naturally occurring CH3 domains and engineered variants of naturally occurring CH2 domains (e.g., CH3 domains comprising one or more amino acid insertions, deletions, substitutions, or modifications relative to a naturally occurring CH3 domain).

[0045] As used herein, the term “hinge region” refers to the portion of an antibody heavy chain comprising the cysteine residues (e.g., the cysteine residues at amino acid positions 226 and 229 of human IgG₁, according to the EU index) that mediate disulphide bonding between two heavy chains in an intact antibody. The term includes naturally occurring hinge regions and engineered variants of naturally occurring hinge regions (e.g., hinge regions comprising one or more amino acid insertions, deletions, substitutions, or modifications relative to a naturally occurring hinge regions). An exemplary full-length IgG₁ hinge region comprises amino acid positions 216-230 of human IgG₁, according to the EU index.

[0046] As used herein, the term “EU index” refers to the EU numbering convention for the constant regions of an antibody, as described in Edelman, GM. et al., *Proc. Natl. Acad. USA*, 63, 78-85 (1969) and Kabat et al., *Sequences of Proteins of Immunological Interest*, U.S. Dept. Health and Human Services, 5th edition, 1991, each of which is herein incorporated by reference in its entirety. All numbering of amino acid positions of the Fc polypeptides, or fragments thereof, used herein is according to the EU index.

[0047] As used herein, the term “antigen-binding moiety” refers to a molecule that specifically binds to an antigen as such binding is understood by one skilled in the art. For example, an antigen-binding moiety that specifically binds to an antigen binds to other molecules, generally with lower affinity as determined by, e.g., immunoassays, BIAcore®, KinExA 3000 instrument (Sapidyne Instruments, Boise, ID), or other assays known in the art. In certain embodiments, an antigen-binding moiety that specifically binds to an antigen binds to the antigen with a K_A that is at least 2 logs (e.g., factors of 10), 2.5 logs, 3 logs, 4 logs or greater than the K_A when the molecule binds non-specifically to another antigen.

[0048] As used herein, the terms “antibody” and “antibodies” include full-length antibodies, antigen-binding fragments of full-length antibodies, and molecules comprising antibody CDRs, VH regions, and/or VL regions. Examples of antibodies include, without limitation, monoclonal

antibodies, recombinantly produced antibodies, monospecific antibodies, multispecific antibodies (including bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, an antibody light chain monomer, an antibody heavy chain monomer, an antibody light chain dimer, an antibody heavy chain dimer, an antibody light chain- antibody heavy chain pair, intrabodies, heteroconjugate antibodies, antibody-drug conjugates, single domain antibodies, monovalent antibodies, single chain antibodies or single-chain Fvs (scFv), camelized antibodies, affibodies, Fab fragments, F(ab')₂ fragments, disulphide-linked Fvs (sdFv), anti-idiotypic (anti-Id) antibodies (including, e.g., anti-anti-Id antibodies), and antigen-binding fragments of any of the above. In certain embodiments, antibodies described herein refer to polyclonal antibody populations. Antibodies can be of any type (e.g., IgG, IgE, IgM, IgD, IgA or IgY), any class (e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁ or IgA₂), or any subclass (e.g., IgG_{2a} or IgG_{2b}) of immunoglobulin molecule. In certain embodiments, antibodies described herein are IgG antibodies, or a class (e.g., human IgG₁ or IgG₄) or subclass thereof.

[0049] As used herein, the the terms “VH” and “VL” refer to antibody heavy and light chain variable domain, respectively, as described in Kabat et al., (1991) Sequences of Proteins of Immunological Interest (NIH Publication No. 91-3242, Bethesda), which is herein incorporated by reference in its entirety.

[0050] As used herein, the the term “VHH” refers to the heavy chain variable domain of a camelid heavy chain-only antibody (HCAb) and humanized variants thereof, as described in Hamers-Casterman C. et al., Nature (1993) 363:446–8.10.1038/363446a0, which is incorporated by reference herein in its entirety.

[0051] As used herein, the term “VH/VL Pair” refers to a combination of a VH and a VL that together form the binding site for an antigen.

[0052] As used herein, the term “heavy chain” when used in reference to an antibody can refer to any distinct type, e.g., alpha (α), delta (δ), epsilon (ε), gamma (γ), and mu (μ), based on the amino acid sequence of the constant domain, which give rise to IgA, IgD, IgE, IgG, and IgM classes of antibodies, respectively, including subclasses of IgG, e.g., IgG₁, IgG₂, IgG₃, and IgG₄.

[0053] As used herein, the term “full-length antibody heavy chain” refers to an antibody heavy chain comprising, from N to C terminal, a VH, a CH1 region, a hinge region, a CH2 domain and a CH3 domain.

[0054] As used herein, the term “light chain” when used in reference to an antibody can refer to any distinct type, e.g., kappa (κ) or lambda (λ) based on the amino acid sequence of the constant domains. Light chain amino acid sequences are well known in the art. In specific embodiments, the light chain is a human light chain.

[0055] As used herein, the term “half-antibody” refers to an antibody heavy chain and an antibody light chain linked to one another in the same manner as the heavy and light chains of an intact, wild-type immunoglobulin. In certain embodiments, a half-antibody is produced by the reduction of the inter-heavy chain disulphide bonds of the hinge region of a full-length antibody. In certain embodiments, a half-antibody is produced by expression of an Fc polypeptide disclosed herein in a cell.

5.2 Heterodimeric Proteins

[0056] In one aspect, the instant disclosure provides heterodimeric proteins comprising a first and a second Fc polypeptide, wherein: the first Fc polypeptide comprises the amino acids aspartate, glutamate, and tryptophan at amino acid positions 239, 332, and 366, respectively; and the second Fc polypeptide comprises the amino acids aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but does not comprise the amino acids glutamate at amino acid position 332, wherein the amino acid positions are numbered according to the EU index in each case. In certain embodiments, the first Fc polypeptide further comprises the amino acid leucine at amino acid position 330, wherein the amino acid positions are numbered according to the EU index. In certain embodiments, the first Fc polypeptide further comprises the amino acid leucine at amino acid position 330 and the second Fc polypeptide does not comprise the amino acid leucine at amino acid position 330, wherein the amino acid positions are numbered according to the EU index.

[0057] In another aspect, the instant disclosure provides heterodimeric proteins comprising a first and a second Fc polypeptide, wherein: the first Fc polypeptide comprises the amino acid tryptophan at amino acid position 366, but does not comprise the amino acids aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively; and the second Fc polypeptide comprises:

(a) the amino acids serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively, but does not comprise the amino acids aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively;

(b) the amino acids aspartate, leucine, serine, alanine, and valine at amino acid positions 239, 330, 366, 368, and 407, respectively, but does not comprise the amino acids glutamate at amino acid position 332;

(c) the amino acids leucine, glutamate, serine, alanine, and valine at amino acid positions 330, 332, 366, 368, and 407, respectively, but does not comprise the amino acid aspartate at amino acid position 239;

(d) the amino acids aspartate, glutamate, serine, alanine, and valine at amino acid positions 239, 332, 366, 368, and 407, respectively, but does comprise the amino acid leucine at amino acid position 330;

(e) the amino acids aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but does not comprise the amino acids leucine and glutamate at amino acid positions 330 and 332, respectively;

(f) the amino acids leucine, serine, alanine, and valine at amino acid positions 330, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and glutamate at amino acid positions 239 and 332, respectively; or

(g) the amino acids glutamate, serine, alanine, and valine at amino acid position 332, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and leucine at amino acid positions 239 and 330, respectively,

wherein the amino acid positions are numbered according to the EU index.

[0058] In another aspect, the instant disclosure provides heterodimeric proteins comprising a first and a second Fc polypeptide, wherein: the first Fc polypeptide comprises the amino acids aspartate, leucine, glutamate, and tryptophan at amino acid positions 239, 330, 332, and 366, respectively; and the second Fc polypeptide comprises:

(a) the amino acids serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively, but does not comprise the amino acids aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively;

(b) the amino acids aspartate, leucine, serine, alanine, and valine at amino acid positions 239, 330, 366, 368, and 407, respectively, but does not comprise the amino acids glutamate at amino acid position 332;

(c) the amino acids leucine, glutamate, serine, alanine, and valine at amino acid positions 330, 332, 366, 368, and 407, respectively, but does not comprise the amino acid aspartate at amino acid position 239;

(d) the amino acids aspartate, glutamate, serine, alanine, and valine at amino acid positions 239, 332, 366, 368, and 407, respectively, but does comprise the amino acid leucine at amino acid position 330;

(e) the amino acids aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but does not comprise the amino acids leucine and glutamate at amino acid positions 330 and 332, respectively;

(f) the amino acids leucine, serine, alanine, and valine at amino acid positions 330, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and glutamate at amino acid positions 239 and 332, respectively; or

(g) the amino acids glutamate, serine, alanine, and valine at amino acid position 332, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and leucine at amino acid positions 239 and 330, respectively,

wherein the amino acid positions are numbered according to the EU index.

[0059] In another aspect, the instant disclosure provides heterodimeric proteins comprising a first and a second Fc polypeptide, wherein: the first Fc polypeptide comprises the amino acids aspartate, leucine, and tryptophan at amino acid positions 239, 330, and 366, respectively, but does not comprise the amino acid glutamate at amino acid position 332; and the second Fc polypeptide comprises:

(a) the amino acids serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively, but does not comprise the amino acids aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively;

(b) the amino acids aspartate, leucine, serine, alanine, and valine at amino acid positions 239, 330, 366, 368, and 407, respectively, but does not comprise the amino acids glutamate at amino acid position 332;

(c) the amino acids leucine, glutamate, serine, alanine, and valine at amino acid positions 330, 332, 366, 368, and 407, respectively, but does not comprise the amino acid aspartate at amino acid position 239;

(d) the amino acids aspartate, glutamate, serine, alanine, and valine at amino acid positions 239, 332, 366, 368, and 407, respectively, but does comprise the amino acid leucine at amino acid position 330;

(e) the amino acids aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but does not comprise the amino acids leucine and glutamate at amino acid positions 330 and 332, respectively;

(f) the amino acids leucine, serine, alanine, and valine at amino acid positions 330, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and glutamate at amino acid positions 239 and 332, respectively; or

(g) the amino acids glutamate, serine, alanine, and valine at amino acid position 332, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and leucine at amino acid positions 239 and 330, respectively,

wherein the amino acid positions are numbered according to the EU index.

[0060] In another aspect, the instant disclosure provides heterodimeric proteins comprising a first and a second Fc polypeptide, wherein: the first Fc polypeptide comprises the amino acids leucine, glutamate, and tryptophan at amino acid positions 330, 332, and 366, respectively, but does not comprise the amino acid aspartate at amino acid position 239; and the second Fc polypeptide comprises:

(a) the amino acids serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively, but does not comprise the amino acids aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively;

(b) the amino acids aspartate, leucine, serine, alanine, and valine at amino acid positions 239, 330, 366, 368, and 407, respectively, but does not comprise the amino acids glutamate at amino acid position 332;

(c) the amino acids leucine, glutamate, serine, alanine, and valine at amino acid positions 330, 332, 366, 368, and 407, respectively, but does not comprise the amino acid aspartate at amino acid position 239;

(d) the amino acids aspartate, glutamate, serine, alanine, and valine at amino acid positions 239, 332, 366, 368, and 407, respectively, but does comprise the amino acid leucine at amino acid position 330;

(e) the amino acids aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but does not comprise the amino acids leucine and glutamate at amino acid positions 330 and 332, respectively;

(f) the amino acids leucine, serine, alanine, and valine at amino acid positions 330, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and glutamate at amino acid positions 239 and 332, respectively; or

(g) the amino acids glutamate, serine, alanine, and valine at amino acid position 332, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and leucine at amino acid positions 239 and 330, respectively,

wherein the amino acid positions are numbered according to the EU index.

[0061] In another aspect, the instant disclosure provides heterodimeric proteins comprising a first and a second Fc polypeptide, wherein: the first Fc polypeptide comprises the amino acids aspartate, glutamate, and tryptophan at amino acid positions 239, 332, and 366, respectively, but does not comprise the amino acid leucine at amino acid position 330; and the second Fc polypeptide comprises:

(a) the amino acids serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively, but does not comprise the amino acids aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively;

(b) the amino acids aspartate, leucine, serine, alanine, and valine at amino acid positions 239, 330, 366, 368, and 407, respectively, but does not comprise the amino acids glutamate at amino acid position 332;

(c) the amino acids leucine, glutamate, serine, alanine, and valine at amino acid positions 330, 332, 366, 368, and 407, respectively, but does not comprise the amino acid aspartate at amino acid position 239;

(d) the amino acids aspartate, glutamate, serine, alanine, and valine at amino acid positions 239, 332, 366, 368, and 407, respectively, but does comprise the amino acid leucine at amino acid position 330;

(e) the amino acids aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but does not comprise the amino acids leucine and glutamate at amino acid positions 330 and 332, respectively;

(f) the amino acids leucine, serine, alanine, and valine at amino acid positions 330, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and glutamate at amino acid positions 239 and 332, respectively; or

(g) the amino acids glutamate, serine, alanine, and valine at amino acid position 332, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and leucine at amino acid positions 239 and 330, respectively,

wherein the amino acid positions are numbered according to the EU index.

[0062] In another aspect, the instant disclosure provides heterodimeric proteins comprising a first and a second Fc polypeptide, wherein: the first Fc polypeptide comprises the amino acids aspartate and tryptophan at amino acid positions 239 and 366, respectively, but does not comprise the amino acids leucine and glutamate at amino acid positions 330 and 332, respectively; and the second Fc polypeptide comprises:

(a) the amino acids serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively, but does not comprise the amino acids aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively;

(b) the amino acids aspartate, leucine, serine, alanine, and valine at amino acid positions 239, 330, 366, 368, and 407, respectively, but does not comprise the amino acids glutamate at amino acid position 332;

(c) the amino acids leucine, glutamate, serine, alanine, and valine at amino acid positions 330, 332, 366, 368, and 407, respectively, but does not comprise the amino acid aspartate at amino acid position 239;

(d) the amino acids aspartate, glutamate, serine, alanine, and valine at amino acid positions 239, 332, 366, 368, and 407, respectively, but does comprise the amino acid leucine at amino acid position 330;

(e) the amino acids aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but does not comprise the amino acids leucine and glutamate at amino acid positions 330 and 332, respectively;

(f) the amino acids leucine, serine, alanine, and valine at amino acid positions 330, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and glutamate at amino acid positions 239 and 332, respectively; or

(g) the amino acids glutamate, serine, alanine, and valine at amino acid position 332, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and leucine at amino acid positions 239 and 330, respectively,

wherein the amino acid positions are numbered according to the EU index.

[0063] In another aspect, the instant disclosure provides heterodimeric proteins comprising a first and a second Fc polypeptide, wherein: the first Fc polypeptide comprises the amino acids leucine and tryptophan at amino acid positions 330 and 366, respectively, but does not comprise the amino acids aspartate and glutamate at amino acid positions 239 and 332, respectively; and the second Fc polypeptide comprises:

(a) the amino acids serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively, but does not comprise the amino acids aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively;

(b) the amino acids aspartate, leucine, serine, alanine, and valine at amino acid positions 239, 330, 366, 368, and 407, respectively, but does not comprise the amino acids glutamate at amino acid position 332;

(c) the amino acids leucine, glutamate, serine, alanine, and valine at amino acid positions 330, 332, 366, 368, and 407, respectively, but does not comprise the amino acid aspartate at amino acid position 239;

(d) the amino acids aspartate, glutamate, serine, alanine, and valine at amino acid positions 239, 332, 366, 368, and 407, respectively, but does comprise the amino acid leucine at amino acid position 330;

(e) the amino acids aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but does not comprise the amino acids leucine and glutamate at amino acid positions 330 and 332, respectively;

(f) the amino acids leucine, serine, alanine, and valine at amino acid positions 330, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and glutamate at amino acid positions 239 and 332, respectively; or

(g) the amino acids glutamate, serine, alanine, and valine at amino acid position 332, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and leucine at amino acid positions 239 and 330, respectively,

wherein the amino acid positions are numbered according to the EU index.

[0064] In another aspect, the instant disclosure provides heterodimeric proteins comprising a first and a second Fc polypeptide, wherein: the first Fc polypeptide comprises the amino acids glutamate and tryptophan at amino acid positions 332 and 366, respectively, but does not comprise the amino acids aspartate and leucine at amino acid positions 239 and 330, respectively; and the second Fc polypeptide comprises:

(a) the amino acids serine, alanine, and valine at amino acid positions 366, 368, and 407, respectively, but does not comprise the amino acids aspartate, leucine, and glutamate at amino acid positions 239, 330, and 332, respectively;

(b) the amino acids aspartate, leucine, serine, alanine, and valine at amino acid positions 239, 330, 366, 368, and 407, respectively, but does not comprise the amino acids glutamate at amino acid position 332;

(c) the amino acids leucine, glutamate, serine, alanine, and valine at amino acid positions 330, 332, 366, 368, and 407, respectively, but does not comprise the amino acid aspartate at amino acid position 239;

(d) the amino acids aspartate, glutamate, serine, alanine, and valine at amino acid positions 239, 332, 366, 368, and 407, respectively, but does comprise the amino acid leucine at amino acid position 330;

(e) the amino acids aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but does not comprise the amino acids leucine and glutamate at amino acid positions 330 and 332, respectively;

(f) the amino acids leucine, serine, alanine, and valine at amino acid positions 330, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and glutamate at amino acid positions 239 and 332, respectively; or

(g) the amino acids glutamate, serine, alanine, and valine at amino acid position 332, 366, 368, and 407, respectively, but does not comprise the amino acids aspartate and leucine at amino acid positions 239 and 330, respectively,

wherein the amino acid positions are numbered according to the EU index.

[0065] The Fc polypeptides described herein generally comprise a CH2 domain and a CH3 domain, wherein the C-terminus of the CH2 domain is linked (directly or indirectly) to the N-terminus of the CH3 domain. Any naturally occurring or variant CH2 and/or CH3 domain can be used in the Fc polypeptides described herein. For example, in certain embodiments, the CH2

and/or CH3 domain is a naturally occurring CH2 or CH3 domain from an IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂ antibody heavy chain, e.g., a human IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂ antibody heavy chain. The CH2 and CH3 domains can be from the same or different antibody heavy chains. In certain embodiments, the Fc polypeptide comprises a CH2 and CH3 domain-containing portion from a single antibody heavy chain. In certain embodiments, the CH2 and/or CH3 domain is a variant of a naturally occurring CH2 or CH3 domain, respectively. In certain embodiments, the CH2 and/or CH3 domain is a variant comprising one or more amino acid insertions, deletion, substitutions, or modifications relative to a naturally occurring CH2 or CH3 domain, respectively. In certain embodiments, the CH2 and/or CH3 domain is a chimera of one or more CH2 or CH3 domains, respectively. In certain embodiments, the CH2 domain comprises amino acid positions 231-340 of a naturally occurring hinge region (e.g., human IgG₁), according to the EU index. In certain embodiments, the CH3 domain comprises amino acid positions 341-447 of a naturally occurring hinge region (e.g., human IgG₁), according to the EU index.

[0066] In certain embodiments, the Fc polypeptides described herein further comprise a hinge region, wherein the C-terminus of hinge region is linked (directly or indirectly) to the N-terminus of the CH2 domain. For example, in certain embodiments, the hinge region is a naturally occurring hinge region from an IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂ antibody heavy chain, e.g., a human IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂ antibody heavy chain. The hinge region can be from the same or different antibody heavy chain than the CH2 and/or CH3 domains. In certain embodiments, the hinge region is a variant comprising one or more amino acid insertions, deletion, substitutions, or modifications relative to a naturally occurring hinge region. In certain embodiments, the hinge region is a chimera of one or more hinge regions. In certain embodiments, the hinge region comprises amino acid positions 226-229 of a naturally occurring hinge region (e.g., human IgG₁), according to the EU index. In certain embodiments, the hinge region comprises amino acid positions 216-230 of a naturally occurring hinge region (e.g., human IgG₁), according to the EU index. In certain embodiments, the hinge region comprises amino acid positions 216-230 of a naturally occurring hinge region (e.g., human IgG₁), according to the EU index. In certain embodiments, the hinge region is a variant IgG₄ hinge region comprising a serine (S) at amino acid position 228, according to the EU index.

[0067] In certain embodiments, the Fc polypeptides described herein further comprise a CH1 domain, wherein the C-terminus of CH1 domain is linked (directly or indirectly) to the N-terminus

of the hinge region. For example, in certain embodiments, the CH1 domain is a naturally occurring CH1 domain from an IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂ antibody heavy chain, e.g., a human IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂ antibody heavy chain. The CH1 domain can be from the same or different antibody heavy chain than the hinge region, CH2 domain and/or CH3 domain. In certain embodiments, the CH1 domain is a variant comprising one or more amino acid insertions, deletions, substitutions, or modifications relative to a naturally occurring CH1 domain. In certain embodiments, the CH1 domain is a chimera of one or more CH1 domain. In certain embodiments, the CH1 domain comprises amino acid positions 118-215 of a naturally occurring hinge region (e.g., human IgG₁), according to the EU index.

[0068] The amino acid sequences of exemplary Fc polypeptides, or portions thereof, are set forth in Table 1 herein.

Table 1. Amino acid sequences of exemplary Fc polypeptides or portions thereof

Description	Amino Acid Sequence	SEQ ID NO
IgG1m3 CH1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRV	1
Consensus CH1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ V wherein X ₁ is R or K	2
Hinge	EPKSCDKTHTCPPCP	3
CH2 wild-type	APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAK	4
CH2 S239D	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAK	5
CH2 S239D/I332E	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPEEKTISKAK	6
CH2 S239D/A330L/ I332E	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPLPEEKTISKAK	7
IgG1m3 CH3	GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMEALHNHYTQKSLSLSPG	8

Description	Amino Acid Sequence	SEQ ID NO
Consensus CH3	GQPREPQVYTLPPSRX ₁ EX ₂ TKNQVSLTCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	9
IgG1m3 CH3 T366W	GQPREPQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPG	10
Consensus CH3 T366W	GQPREPQVYTLPPSRX ₁ EX ₂ TKNQVSLWCLVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	11
IgG1m3 CH3 T366S/L368A/ Y407V	GQPREPQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPG	12
Consensus CH3 T366S/L368A/ Y407V	GQPREPQVYTLPPSRX ₁ EX ₂ TKNQVSLSCAVKGFYPSDIAV EWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQ GNVFSCSVMHEX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	13
IgG1m3 Constant Region	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVPEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPG	14
Consensus Constant Region	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	15

Description	Amino Acid Sequence	SEQ ID NO
IgG1m3 Constant Region S239D	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHNHYT QKSLSLSPG	16
Consensus Constant Region S239D	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	17
IgG1m3 Constant Region S239D/I332E	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHNHYT QKSLSLSPG	18
Consensus Constant Region S239D/I332E	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	19

Description	Amino Acid Sequence	SEQ ID NO
IgG1m3 Constant Region S239D/A330L/ I332E	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVMSVHEALHNHYT QKSLSLSPG	20
Consensus Constant Region S239D/A330L/ I332E	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVMSVHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	21
IgG1m3 Constant Region T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVMSVHEALHNHYT QKSLSLSPG	22
Consensus Constant Region T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVMSVHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	23

Description	Amino Acid Sequence	SEQ ID NO
IgG1m3 Constant Region S239D/A330L/ I332E/ T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVKPKCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHNHYT QKSLSLSPG	24
Consensus Constant Region S239D/A330L/ I332E/ T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	25
IgG1m3 Constant Region S239D/I332E/ T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVKPKCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHNHYT QKSLSLSPG	26
Consensus Constant Region S239D/I332E/ T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	27

Description	Amino Acid Sequence	SEQ ID NO
IgG1m3 Constant Region S239D/ T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVKPKCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEALHNHYT QKSLSLSPG	28
Consensus Constant Region S239D/ T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSVSMHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	29
IgG1m3 Constant Region T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVKPKCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSVSMHEALHNHYT QKSLSLSPG	30
Consensus Constant Region T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSVSMHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	31

Description	Amino Acid Sequence	SEQ ID NO
IgG1m3 Constant Region S239D/A330L/ I332E/ T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSVMSVHEALHNHYT QKSLSLSPG	32
Consensus Constant Region S239D/A330L/ I332E/ T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSVMSVHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	33
IgG1m3 Constant Region S239D/I332E/ T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSVMSVHEALHNHYT QKSLSLSPG	34
Consensus Constant Region S239D/I332E/ T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSVMSVHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	35

Description	Amino Acid Sequence	SEQ ID NO
IgG1m3 Constant Region S239D/ T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVKPKCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSVMSVHEALHNHYT QKSLSLSPG	36
Consensus Constant Region S239D/ T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKX ₁ VEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRX ₂ E X ₃ TKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSVMSVHEX ₄ LHNHYT QKSLSLSPG wherein X ₁ is R or K; X ₂ is E or D; X ₃ is M or L; and X ₄ is A or G	37
IgG1m3 Constant Region CH2-CH3	APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN YKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVMSVHE ALHNHYTQKSLSLSPG	38
Consensus Constant Region CH2-CH3	APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSRX ₁ EX ₂ TKNQVSLTCLVKGFYPSDIAVEWESNGQPE NYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVMSV EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	39
IgG1m3 Constant Region CH2-CH3 S239D	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN YKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSVMSVHE ALHNHYTQKSLSLSPG	40

Description	Amino Acid Sequence	SEQ ID NO
Consensus Constant Region CH2-CH3 S239D	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSRX ₁ EX ₂ TKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMH EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	41
IgG1m3 Constant Region CH2-CH3 S239D/I332E	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHE ALHNHYTQKSLSLSPG	42
Consensus Constant Region CH2-CH3 S239D/I332E	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYT LPPSRX ₁ EX ₂ TKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMH EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	43
IgG1m3 Constant Region CH2-CH3 S239D/A330L/ I332E	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN YKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHE ALHNHYTQKSLSLSPG	44
Consensus Constant Region CH2-CH3 S239D/A330L/ I332E	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYT LPPSRX ₁ EX ₂ TKNQVSLTCLVKGFYPSDIAVEWESNGQPEN NYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMH EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	45
IgG1m3 Constant Region CH2-CH3 T366W	APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN YKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHE ALHNHYTQKSLSLSPG	46

Description	Amino Acid Sequence	SEQ ID NO
Consensus Constant Region CH2-CH3 T366W	APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSRX ₁ EX ₂ TKNQVSLWCLVKGFYPSDIAVEWESNGQPEN NYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	47
IgG1m3 Constant Region CH2-CH3 S239D/A330L/ I332E/ T366W	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN YKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG	48
Consensus Constant Region CH2-CH3 S239D/A330L/ I332E/ T366W	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYT LPPSRX ₁ EX ₂ TKNQVSLWCLVKGFYPSDIAVEWESNGQPEN NYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	49
IgG1m3 Constant Region CH2-CH3 S239D/I332E/ T366W	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN YKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG	50
Consensus Constant Region CH2-CH3 S239D/I332E/ T366W	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYT LPPSRX ₁ EX ₂ TKNQVSLWCLVKGFYPSDIAVEWESNGQPEN NYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	51
IgG1m3 Constant Region CH2-CH3 S239D/ T366W	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNGQPENN YKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG	52

Description	Amino Acid Sequence	SEQ ID NO
Consensus Constant Region CH2-CH3 S239D/ T366W	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSRX ₁ EX ₂ TKNQVSLWCLVKGFYPSDIAVEWESNGQPEN NYKTTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMH EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	53
IgG1m3 Constant Region CH2-CH3 T366S/L368A/ Y407V	APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG	54
Consensus Constant Region CH2-CH3 T366S/L368A/ Y407V	APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYT LPPSRX ₁ EX ₂ TKNQVSLSCAVKGFYPSDIAVEWESNGQPEN NYKTTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMH EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	55
IgG1m3 Constant Region CH2-CH3 S239D/A330L/ I332E/ T366S/L368A/ Y407V	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG	56
Consensus Constant Region CH2-CH3 S239D/A330L/ I332E/ T366S/L368A/ Y407V	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYT LPPSRX ₁ EX ₂ TKNQVSLSCAVKGFYPSDIAVEWESNGQPEN NYKTTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMH EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	57
IgG1m3 Constant Region CH2-CH3 S239D/I332E/ T366S/L368A/ Y407V	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPREPQVYT LPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPENN YKTTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPG	58

Description	Amino Acid Sequence	SEQ ID NO
Consensus Constant Region CH2-CH3 S239D/I332E/ T366S/L368A/ Y407V	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPKEKTISKAKGQPREPQVY TLPSSRX ₁ EX ₂ TKNQVSLSCAVKGFYPSDIAVEWESNGQPEN NYKTTTPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMH EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	59
IgG1m3 Constant Region CH2-CH3 S239D/ T366S/L368A/ Y407V	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY TLPSSREEMTKNQVSLSCAVKGFYPSDIAVEWESNGQPEN NYKTTTPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMH EALHNHYTQKSLSLSPG	60
Consensus Constant Region CH2-CH3 S239D/ T366S/L368A/ Y407V	APELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY TLPSSRX ₁ EX ₂ TKNQVSLSCAVKGFYPSDIAVEWESNGQPEN NYKTTTPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMH EX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	61
IgG1m3 Fc Region S239D/A330L/ I332E/ T366W	CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNG QPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPG	62
Consensus Fc Region S239D/A330L/ I332E/ T366W	CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPRE PQVYTLPPSRX ₁ EX ₂ TKNQVSLWCLVKGFYPSDIAVEWESN GQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVMHEX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	63
IgG1m3 Fc Region S239D/I332E/ T366W	CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPKEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNG QPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPG	64

Description	Amino Acid Sequence	SEQ ID NO
Consensus Fc Region S239D/I332E/ T366W	CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPAEKTISKAKGQPRE PQVYTLPPSRX ₁ EX ₂ TKNQVSLWCLVKGFYPSDIAVEWESN GQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFS CSVMHEX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	65
IgG1m3 Fc Region S239D/ T366S/L368A/ Y407V	CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNG QPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPG	66
Consensus Fc Region S239D/ T366S/L368A/ Y407V	CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVYTLPPSRX ₁ EX ₂ TKNQVSLSCAVKGFYPSDIAVEWESN GQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQQGNVFS CSVMHEX ₃ LHNHYTQKSLSLSPG wherein X ₁ is E or D; X ₂ is M or L; and X ₃ is A or G	67
IgG1m3 Constant Region S239D/A330L/ T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVKPKCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPG	68
IgG1m3 Constant Region A330L/ T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVKPKCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT QKSLSLSPG	69

Description	Amino Acid Sequence	SEQ ID NO
IgG1m3 Constant Region I332E/ T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSFSVMHEALHNHYT QKSLSLSPG	70
IgG1m3 Constant Region S239D/A330L/ T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSFSVMHEALHNHYT QKSLSLSPG	71
IgG1m3 Constant Region A330L/I332E/ T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSFSVMHEALHNHYT QKSLSLSPG	72
IgG1m3 Constant Region A330L/ T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSFSVMHEALHNHYT QKSLSLSPG	73
IgG1m3 Constant Region I332E/ T366S/L368A/ Y407V	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPEEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTPPV LDSDGSFFLVSKLTVDKSRWQQGNVFSFSVMHEALHNHYT QKSLSLSPG	74

Description	Amino Acid Sequence	SEQ ID NO
IgG1m3 Constant Region A330L/I332E/ T366W	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQT YICNVNHKPSNTKVDKRVKPKCDKTHTCPPCPAPELLGG PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNW YVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYT QKSLSLSPG	75
IgG1m3 Fc Region S239D/A330L/ T366W	CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPLPIEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNG QPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCF SVMHEALHNHYTQKSLSLSPG	76
IgG1m3 Fc Region A330L/ T366W	CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPLPIEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNG QPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCF SVMHEALHNHYTQKSLSLSPG	77
IgG1m3 Fc Region I332E/ T366W	CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPEEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNG QPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCF SVMHEALHNHYTQKSLSLSPG	78
IgG1m3 Fc Region S239D/A330L/ T366S/L368A/ Y407V	CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPLPIEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNG QPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFCF SVMHEALHNHYTQKSLSLSPG	79
IgG1m3 Fc Region A330L/I332E/ T366S/L368A/ Y407V	CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNG QPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFCF SVMHEALHNHYTQKSLSLSPG	80
IgG1m3 Fc Region A330L/ T366S/L368A/ Y407V	CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPLPIEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNG QPENNYKTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFCF SVMHEALHNHYTQKSLSLSPG	81

Description	Amino Acid Sequence	SEQ ID NO
IgG1m3 Fc Region I332E/ T366S/L368A/ Y407V	CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPKEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNG QPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPG	82
IgG1m3 Fc Region A330L/I332E/ T366W	CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNG QPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPG	83
IgG1m3 Fc Region T366W	CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNG QPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPG	84
IgG1m3 Fc Region S239D/ T366W	CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLWCLVKGFYPSDIAVEWESNG QPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPG	85
IgG1m3 Fc Region T366S/L368A/ Y407V	CPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNG QPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPG	86
IgG1m3 Fc Region S239D/I332E/ T366S/L368A/ Y407V	CPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV LTVLHQDWLNGKEYKCKVSNKALPAPKEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLSCAVKGFYPSDIAVEWESNG QPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQQGNVFSC SVMHEALHNHYTQKSLSLSPG	87

[0069] In certain embodiments, the heterodimeric protein comprises: a first Fc polypeptide comprising an amino acid sequence that is at least 75% identical (e.g., at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical) to the amino acid sequence of SEQ ID NO: 24, 25, 26, 27, 48, 49, 50, 51, 62, 63, 64, or 65; and/or a second Fc polypeptide comprising an amino acid sequence that is at least 75% identical (e.g., at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99,

or 100% identical) to the amino acid sequence of SEQ ID NO: 36, 37, 60, 61, 66 or 67. In certain embodiments, the first Fc polynucleotide comprises the amino acid sequence of SEQ ID NO: 24, 25, 26, 27, 48, 49, 50, 51, 62, 63, 64, or 65; and/or the second Fc polynucleotide comprises the amino acid sequence of SEQ ID NO: 36, 37, 60, 61, 66 or 67. Exemplary pairs of amino acid sequences that can be incorporated into the first and second Fc polypeptides of heterodimeric proteins are set forth in Table 2 herein. In certain, embodiments, the first Fc polypeptide and the second Fc polypeptide, respectively, comprise the amino acid sequences set forth in the first and second column of any row of Table 2.

Table 2. Exemplary pairs of amino acid sequences that can be incorporated into first and second Fc polypeptides

SEQ ID NO of first Fc polypeptide sequence	SEQ ID NO of second Fc polypeptide sequence
24	36
24	37
25	36
25	37
26	36
26	37
27	36
27	37
48	60
48	61
49	60
49	61
50	60
50	61

SEQ ID NO of first Fc polypeptide sequence	SEQ ID NO of second Fc polypeptide sequence
51	60
51	61
62	66
62	67
63	66
63	67
64	66
64	67
65	66
65	67

[0070] In certain embodiments, the first Fc polypeptide and second Fc polypeptide comprise amino acid sequences that are at least 75% identical (e.g., at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical) to the amino acid sequence of SEQ ID NOs: 24 and 36; 24 and 37; 25 and 36; 25 and 37; 26 and 36; 26 and 37; 27 and 36; 27 and 37; 48 and 60; 48 and 61; 49 and 60; 49 and 61; 50 and 60; 50 and 61; 51 and 60; 51 and 61; 62 and 66; 62 and 67; 63 and 66; 63 and 67; 64 and 66; 64 and 67; 65 and 66; or 65 and 67, respectively. In certain embodiments, the first Fc polypeptide and second Fc polypeptide comprise the amino acid sequences of SEQ ID NOs: 24 and 36; 24 and 37; 25 and 36; 25 and 37; 26 and 36; 26 and 37; 27 and 36; 27 and 37; 48 and 60; 48 and 61; 49 and 60; 49 and 61; 50 and 60; 50 and 61; 51 and 60; 51 and 61; 62 and 66; 62 and 67; 63 and 66; 63 and 67; 64 and 66; 64 and 67; 65 and 66; or 65 and 67, respectively.

[0071] In an embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 22 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 30, 34, 36, 71, 72, 73, or 74. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 24 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 30, 34, 36, 71, 72, 73, or 74. In another embodiment, the first Fc

polypeptide comprises the amino acid sequence of SEQ ID NO: 68 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 30, 34, 36, 71, 72, 73, or 74. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 26 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 30, 34, 36, 71, 72, 73, or 74. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 75 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 30, 34, 36, 71, 72, 73, or 74. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 28 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 30, 34, 36, 71, 72, 73, or 74. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 69 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 30, 34, 36, 71, 72, 73, or 74. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 70 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 30, 34, 36, 71, 72, 73, or 74.

[0072] In an embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 84 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 66, 79, 80, 81, 82, 86, or 87. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 62 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 66, 79, 80, 81, 82, 86, or 87. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 76 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 66, 79, 80, 81, 82, 86, or 87. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 64 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 66, 79, 80, 81, 82, 86, or 87. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 83 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 66, 79, 80, 81, 82, 86, or 87. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 85 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 66, 79, 80, 81, 82, 86, or 87. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 77 and the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 66, 79, 80, 81, 82, 86, or 87. In another embodiment, the first Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 78 and

the second Fc polypeptide comprises the amino acid sequence of SEQ ID NO: 66, 79, 80, 81, 82, 86, or 87.

[0073] In certain embodiments, the first and/or the second Fc polypeptide further comprises one or more antigen-binding moieties. An antigen-binding moiety can be linked (directly or indirectly) to any portion of an Fc polypeptide. For example, antigen-binding moieties can be linked (directly or indirectly) to the N and/or C terminus of an Fc polypeptide. Additionally or alternatively, antigen-binding moieties can be linked together in tandem in an Fc polypeptide.

[0074] In certain embodiments, the first and the second Fc polypeptides in a heterodimeric protein each comprise one or more antigen-binding moieties. In such embodiments, each of the antigen-binding moieties can bind to the same or different antigens. In certain embodiments, the heterodimeric protein comprises: a first Fc polypeptide comprising a first antigen-binding moiety that binds to a first antigen; and a second Fc polypeptide comprising a second antigen-binding moiety that binds to a second antigen, wherein the first and second antigen are different (e.g., different molecules or different regions of the same molecule).

[0075] Any type of binding moiety that can be linked to an Fc polypeptide is suitable for use in the heterodimeric proteins disclosed herein. In certain embodiments, the binding moiety comprises an antibody variable domain. Exemplary binding moieties comprising an antibody variable domain include, without limitation, a VH, a VL, a VHH, a VH/VL pair, an scFv, a diabody, or a Fab. In certain embodiments, the binding moiety comprises a ligand. Exemplary ligands include, without limitation, hormones and growth factors, and analogues and mimetics thereof. In certain embodiments, the binding moiety comprises an extracellular domain of cell surface receptor. Exemplary cell surface receptors include, without limitation, a tumor necrosis factor superfamily receptor, a vascular endothelial growth factor receptor, or a transforming growth factor receptor. Such extracellular domains of cell surface receptors are well known in the art to be useful for sequestering the natural ligands of the receptors. Other binding moieties that are suitable for use in the heterodimeric proteins disclosed herein, include, without limitation, lipocalins (see e.g., Gebauer M. et al., 2012, *Method Enzymol* 503:157–188, which is incorporated by reference herein in its entirety), adnectins (see e.g., Lipovsek D., 2011, *Protein Eng Des Sel* 24:3–9, which is incorporated by reference herein in its entirety), avimers (see e.g., Silverman J, et al., 2005, *Nat Biotechnol* 23:1556–1561, which is incorporated by reference herein in its entirety), fynomers (see e.g., Schlatter D, et al., 2012, *mAbs* 4:497–508, which is incorporated by

reference herein in its entirety), kunitz domains (see e.g., Hosse R.J. et al., 2006, Protein Sci 15:14–27, which is incorporated by reference herein in its entirety), knottins (see e.g., Kintzing J.R. et al., 2016, Curr Opin Chem Biol 34:143–150, which is incorporated by reference herein in its entirety), affibodies (see e.g., Feldwisch J. et al., 2010 J Mol Biol 398:232–247, which is incorporated by reference herein in its entirety), and DARPinS (see e.g., Pluckthun A., 2015, Annu Rev Pharmacol Toxicol 55:489–511, which is incorporated by reference herein in its entirety).

[0076] In certain embodiments, the first and/or the second Fc polypeptides in a heterodimeric protein each comprises an antibody heavy chain. The antibody heavy chain can be a full-length antibody heavy chain or variant antibody heavy chain comprising one or more amino acid insertions, deletions, substitutions, or modifications relative to a naturally occurring full-length antibody heavy chain. In certain embodiments, the antibody heavy chain lacks a CH1 domain or comprises mutations in a CH1 domain or heavy chain variable domain that prevent association of the heavy chain with an antibody light chain. In certain embodiments, the antibody heavy chain lacks a portion of a hinge region.

[0077] Any species and isotype of antibody heavy chain can be used in the heterodimeric proteins disclosed herein. In certain embodiments, the first and/or the second Fc polypeptide comprises a human IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂ antibody heavy chain or variant thereof. In certain embodiments, the first and/or the second Fc polypeptide comprises an antibody heavy chain that is a chimera of one or more human IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂ antibody heavy chains.

[0078] In certain embodiments, the first and/or second Fc polypeptide comprises an antibody heavy chain and an antibody light chain (e.g., a human kappa or lambda light chain). The light chain can be linked (directly or indirectly) to any portion of the antibody heavy chain. In certain embodiments, the antibody heavy chain and the antibody light chain are linked to one another by disulphide bonds such that they form a half-antibody.

[0079] In certain embodiments, the heterodimeric protein comprises: a first Fc polypeptide comprising a first antibody heavy chain and a first antibody light chain that form a first half-antibody; and a second Fc polypeptide comprising a second antibody heavy chain and a second antibody light chain that form a second half-antibody. The first and the second half-antibodies can bind to the same antigen or different antigens (e.g., different molecules or different regions of the same molecule).

[0080] In certain embodiments, the CH3 domain of any of the first and/or second Fc polypeptides disclosed herein further comprises a C-terminal lysine. For example, in certain embodiments, any one of the CH3 domain-containing amino sequences disclosed in Table 1 can further comprise a lysine at the C-terminus of the CH3 domain.

[0081] In certain embodiments, the heterodimeric proteins disclosed herein exhibit improved biophysical properties (e.g., expression levels, solubility, thermal stability, manufacturability, and/or immunogenicity) relative to a corresponding prior art heterodimeric protein (e.g., multispecific antibody). In certain embodiments, the heterodimeric proteins disclosed herein exhibit improved thermal stability and manufacturability.

5.3 Pharmaceutical Compositions

[0082] Provided herein are compositions comprising a heterodimeric protein having the desired degree of purity in a physiologically acceptable carrier, excipient or stabilizer (see, e.g., Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA). Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).

[0083] In a specific embodiment, pharmaceutical compositions comprise a heterodimeric protein disclosed herein, and optionally one or more additional prophylactic or therapeutic agents, in a pharmaceutically acceptable carrier. In a specific embodiment, pharmaceutical compositions comprise an effective amount of a heterodimeric protein described herein, and optionally one or more additional prophylactic or therapeutic agents, in a pharmaceutically acceptable carrier. In

certain embodiments, the heterodimeric protein is the only active ingredient included in the pharmaceutical composition. Pharmaceutical compositions described herein can be useful in treating a condition, such as cancer or an infectious disease. In one embodiment, the present invention relates to a pharmaceutical composition of the present invention comprising a heterodimeric protein of the present invention for use as a medicament. In another embodiment, the present invention relates to a pharmaceutical composition of the present invention for use in a method for the treatment of cancer or an infectious disease.

[0084] Pharmaceutically acceptable carriers used in parenteral preparations include aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents and other pharmaceutically acceptable substances. Examples of aqueous vehicles include Sodium Chloride Injection, Ringers Injection, Isotonic Dextrose Injection, Sterile Water Injection, Dextrose and Lactated Ringers Injection. Nonaqueous parenteral vehicles include fixed oils of vegetable origin, cottonseed oil, corn oil, sesame oil and peanut oil. Antimicrobial agents in bacteriostatic or fungistatic concentrations can be added to parenteral preparations packaged in multiple-dose containers which include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride and benzethonium chloride. Isotonic agents include sodium chloride and dextrose. Buffers include phosphate and citrate. Antioxidants include sodium bisulfate. Local anesthetics include procaine hydrochloride. Suspending and dispersing agents include sodium carboxymethylcellulose, hydroxypropyl methylcellulose and polyvinylpyrrolidone. Emulsifying agents include Polysorbate 80 (TWEEN[®] 80). A sequestering or chelating agent of metal ions includes EDTA. Pharmaceutical carriers also include ethyl alcohol, polyethylene glycol and propylene glycol for water miscible vehicles; and sodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.

[0085] A pharmaceutical composition may be formulated for any route of administration to a subject. Specific examples of routes of administration include intranasal, oral, pulmonary, transdermal, intradermal, and parenteral. Parenteral administration, characterized by either subcutaneous, intramuscular or intravenous injection, is also contemplated herein. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. The injectables, solutions

and emulsions also contain one or more excipients. Suitable excipients are, for example, water, saline, dextrose, glycerol or ethanol. In addition, if desired, the pharmaceutical compositions to be administered can also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, and other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate and cyclodextrins.

[0086] Preparations for parenteral administration of a heterodimeric protein include sterile solutions ready for injection, sterile dry soluble products, such as lyophilized powders, ready to be combined with a solvent just prior to use, including hypodermic tablets, sterile suspensions ready for injection, sterile dry insoluble products ready to be combined with a vehicle just prior to use and sterile emulsions. The solutions may be either aqueous or nonaqueous.

[0087] If administered intravenously, suitable carriers include physiological saline or phosphate buffered saline (PBS), and solutions containing thickening and solubilizing agents, such as glucose, polyethylene glycol, and polypropylene glycol and mixtures thereof.

[0088] Topical mixtures comprising a heterodimeric protein are prepared as described for the local and systemic administration. The resulting mixture can be a solution, suspension, emulsions or the like and can be formulated as creams, gels, ointments, emulsions, solutions, elixirs, lotions, suspensions, tinctures, pastes, foams, aerosols, irrigations, sprays, suppositories, bandages, dermal patches or any other formulations suitable for topical administration.

[0089] A heterodimeric protein disclosed herein can be formulated as an aerosol for topical application, such as by inhalation (see, e.g., U.S. Patent Nos. 4,044,126, 4,414,209 and 4,364,923, which describe aerosols for delivery of a steroid useful for treatment of inflammatory diseases, particularly asthma and are herein incorporated by reference in their entireties). These formulations for administration to the respiratory tract can be in the form of an aerosol or solution for a nebulizer, or as a microfine powder for insufflations, alone or in combination with an inert carrier such as lactose. In such a case, the particles of the formulation will, in one embodiment, have diameters of less than 50 microns, in one embodiment less than 10 microns.

[0090] A heterodimeric protein disclosed herein can be formulated for local or topical application, such as for topical application to the skin and mucous membranes, such as in the eye, in the form of gels, creams, and lotions and for application to the eye or for intracisternal or intraspinal application. Topical administration is contemplated for transdermal delivery and also

for administration to the eyes or mucosa, or for inhalation therapies. Nasal solutions of the heterodimeric protein alone or in combination with other pharmaceutically acceptable excipients can also be administered.

[0091] Transdermal patches, including iontophoretic and electrophoretic devices, are well known to those of skill in the art, and can be used to administer a heterodimeric protein. For example, such patches are disclosed in U.S. Patent Nos. 6,267,983, 6,261,595, 6,256,533, 6,167,301, 6,024,975, 6,010,715, 5,985,317, 5,983,134, 5,948,433, and 5,860,957, all of which are herein incorporated by reference in their entireties.

[0092] In certain embodiments, a pharmaceutical composition comprising a heterodimeric protein described herein is a lyophilized powder, which can be reconstituted for administration as solutions, emulsions and other mixtures. It may also be reconstituted and formulated as solids or gels. The lyophilized powder is prepared by dissolving heterodimeric protein described herein, or a pharmaceutically acceptable derivative thereof, in a suitable solvent. In certain embodiments, the lyophilized powder is sterile. The solvent may contain an excipient which improves the stability or other pharmacological component of the powder or reconstituted solution, prepared from the powder. Excipients that may be used include, but are not limited to, dextrose, sorbitol, fructose, corn syrup, xylitol, glycerin, glucose, sucrose or other suitable agent. The solvent may also contain a buffer, such as citrate, sodium or potassium phosphate or other such buffer known to those of skill in the art at, in one embodiment, about neutral pH. Subsequent sterile filtration of the solution followed by lyophilization under standard conditions known to those of skill in the art provides the desired formulation. In one embodiment, the resulting solution will be apportioned into vials for lyophilization. Each vial will contain a single dosage or multiple dosages of the compound. The lyophilized powder can be stored under appropriate conditions, such as at about 4°C to room temperature. Reconstitution of this lyophilized powder with water for injection provides a formulation for use in parenteral administration. For reconstitution, the lyophilized powder is added to sterile water or other suitable carrier. The precise amount depends upon the selected compound. Such amount can be empirically determined.

[0093] Heterodimeric proteins and other compositions provided herein can also be formulated to be targeted to a particular tissue, receptor, or other area of the body of the subject to be treated. Many such targeting methods are well known to those of skill in the art. All such targeting methods are contemplated herein for use in the instant compositions. For non-limiting examples of

targeting methods, see, e.g., U.S. Patent Nos. 6,316,652, 6,274,552, 6,271,359, 6,253,872, 6,139,865, 6,131,570, 6,120,751, 6,071,495, 6,060,082, 6,048,736, 6,039,975, 6,004,534, 5,985,307, 5,972,366, 5,900,252, 5,840,674, 5,759,542 and 5,709,874, all of which are herein incorporated by reference in their entireties. In a specific embodiment, a heterodimeric protein described herein is targeted to a tumor.

[0094] The compositions to be used for *in vivo* administration can be sterile. This is readily accomplished by filtration through, e.g., sterile filtration membranes.

5.4 Polynucleotides, Vectors and Methods of Producing Heterodimeric Proteins

[0095] In another aspect, provided herein are polynucleotides comprising a nucleotide sequence encoding Fc polypeptides described herein, and vectors, e.g., vectors comprising such polynucleotides for recombinant expression in host cells (e.g., *E. coli* and mammalian cells). Provided herein are polynucleotides comprising nucleotide sequences encoding the first and/or second Fc polypeptide of the heterodimeric proteins provided herein, as well as vectors comprising such polynucleotide sequences, e.g., expression vectors for their efficient expression in host cells, e.g., mammalian cells.

[0096] As used herein, an “isolated” polynucleotide or nucleic acid molecule is one which is separated from other nucleic acid molecules which are present in the natural source (e.g., in a mouse or a human) of the nucleic acid molecule. Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. For example, the language “substantially free” includes preparations of polynucleotide or nucleic acid molecule having less than about 15%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% (in particular less than about 10%) of other material, e.g., cellular material, culture medium, other nucleic acid molecules, chemical precursors and/or other chemicals. In a specific embodiment, a nucleic acid molecule(s) encoding an Fc polypeptide described herein is isolated or purified.

[0097] In particular aspects, provided herein are polynucleotides comprising nucleotide sequences encoding Fc polypeptides. In certain aspects, provided herein are polynucleotides comprising a nucleotide sequence encoding the first and/or second Fc polypeptide of the heterodimeric proteins described herein.

[0098] Also provided herein are polynucleotides encoding Fc polypeptides that are optimized,

e.g., by codon/RNA optimization, replacement with heterologous signal sequences, and elimination of mRNA instability elements. Methods to generate optimized nucleic acids encoding Fc polypeptides for recombinant expression by introducing codon changes and/or eliminating inhibitory regions in the mRNA can be carried out by adapting the optimization methods described in, e.g., U.S. Patent Nos. 5,965,726; 6,174,666; 6,291,664; 6,414,132; and 6,794,498, accordingly, all of which are herein incorporated by reference in their entireties. For example, potential splice sites and instability elements (e.g., A/T or A/U rich elements) within the RNA can be mutated without altering the amino acids encoded by the nucleic acid sequences to increase stability of the RNA for recombinant expression. The alterations utilize the degeneracy of the genetic code, e.g., using an alternative codon for an identical amino acid. In certain embodiments, it can be desirable to alter one or more codons to encode a conservative mutation, e.g., a similar amino acid with similar chemical structure and properties and/or function as the original amino acid. Such methods can increase expression of an Fc polypeptide by at least 1 fold, 2 fold, 3 fold, 4 fold, 5 fold, 10 fold, 20 fold, 30 fold, 40 fold, 50 fold, 60 fold, 70 fold, 80 fold, 90 fold, or 100 fold or more relative to the expression of an Fc polypeptide encoded by polynucleotides that have not been optimized.

[0099] In certain embodiments, an optimized polynucleotide sequence encoding an Fc polypeptide can hybridize to an antisense (e.g., complementary) polynucleotide of an unoptimized polynucleotide sequence encoding an Fc polypeptide described herein. In specific embodiments, an optimized nucleotide sequence encoding an Fc polypeptide described herein hybridizes under high stringency conditions to antisense polynucleotide of an unoptimized polynucleotide sequence encoding an Fc polypeptide described herein. In a specific embodiment, an optimized nucleotide sequence encoding an Fc polypeptide described herein hybridizes under high stringency, intermediate or lower stringency hybridization conditions to an antisense polynucleotide of an unoptimized nucleotide sequence encoding an Fc polypeptide described herein. Information regarding hybridization conditions has been described, see, e.g., U.S. Patent Application Publication No. US 2005/0048549 (e.g., paragraphs 72-73), which is herein incorporated by reference in its entirety.

[00100] The polynucleotides can be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. Nucleotide sequences encoding Fc polypeptides described herein and modified versions of these Fc polypeptides can be determined using methods well known in the art, i.e., nucleotide codons known to encode particular amino

acids are assembled in such a way to generate a nucleic acid that encodes the Fc polypeptide. Such a polynucleotide encoding the Fc polypeptide can be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier G et al., (1994), *BioTechniques* 17: 242-6, herein incorporated by reference in its entirety), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence encoding an Fc polypeptide, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

[00101] Alternatively, a polynucleotide encoding an Fc polypeptide described herein can be generated from nucleic acid from a suitable source using methods well known in the art (e.g., PCR and other molecular cloning methods). PCR amplification methods can be used to obtain nucleic acids comprising the sequence encoding the first and/or second Fc polypeptide of a heterodimeric protein. The amplified nucleic acids can be cloned into vectors for expression in host cells and for further cloning.

[00102] If a clone containing a nucleic acid encoding a particular Fc polypeptide is not available, but the sequence of the Fc polypeptide molecule is known, a nucleic acid encoding the Fc polypeptide can be chemically synthesized or obtained from a suitable source (e.g., a cDNA library generated from, or nucleic acid, preferably poly A⁺ RNA, isolated from, any tissue or cells expressing the Fc polypeptide) by PCR amplification using synthetic primers hybridizable to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the Fc polypeptide. Amplified nucleic acids generated by PCR can then be cloned into replicable cloning vectors using any method well known in the art.

[00103] DNA encoding Fc polypeptides described herein can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heterodimeric protein. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as *E. coli* cells, simian COS cells, Chinese hamster ovary (CHO) cells (e.g., CHO cells from the CHO GS System™ (Lonza)), or myeloma cells that do not otherwise produce the Fc polypeptide, to obtain the synthesis of the Fc polypeptide in the recombinant host cells.

[00104] Also provided are polynucleotides that hybridize under high stringency, intermediate or lower stringency hybridization conditions to polynucleotides that encode an Fc polypeptide described herein. In specific embodiments, polynucleotides described herein hybridize under high

stringency, intermediate or lower stringency hybridization conditions to polynucleotides encoding the first and/or second Fc polypeptide of a heterodimeric protein provided herein.

[00105] Hybridization conditions have been described in the art and are known to one of skill in the art. For example, hybridization under stringent conditions can involve hybridization to filter-bound DNA in 6x sodium chloride/sodium citrate (SSC) at about 45° C followed by one or more washes in 0.2xSSC/0.1% SDS at about 50-65° C; hybridization under highly stringent conditions can involve hybridization to filter-bound nucleic acid in 6xSSC at about 45° C followed by one or more washes in 0.1xSSC/0.2% SDS at about 68° C. Hybridization under other stringent hybridization conditions are known to those of skill in the art and have been described, see, for example, Ausubel FM et al., eds., (1989) Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York at pages 6.3.1-6.3.6 and 2.10.3, which is herein incorporated by reference in its entirety.

[00106] In certain aspects, provided herein are cells (e.g., host cells) expressing (e.g., recombinantly) Fc polypeptides described herein and related polynucleotides and expression vectors. Provided herein are vectors (e.g., expression vectors) comprising polynucleotides comprising nucleotide sequences encoding Fc polypeptides for recombinant expression in host cells, preferably in mammalian cells (e.g., CHO cells). Also provided herein are host cells comprising such vectors for recombinantly expressing Fc polypeptides described herein. In a particular aspect, provided herein are methods for producing Fc polypeptides described herein, comprising expressing such Fc polypeptides from a host cell.

[00107] Recombinant expression of Fc polypeptides described herein generally involves construction of an expression vector containing a polynucleotide that encodes the Fc polypeptide. Once a polynucleotide encoding an Fc polypeptide described herein has been obtained, the vector for the production of the Fc polypeptide molecule can be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an Fc polypeptide encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing Fc polypeptide coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* genetic recombination. Also provided are replicable vectors comprising a nucleotide sequence encoding an Fc polypeptide described herein operably

linked to a promoter.

[00108] An expression vector can be transferred to a cell (e.g., host cell) by conventional techniques and the resulting cells can then be cultured by conventional techniques to produce an Fc polypeptide described herein. Thus, provided herein are host cells containing a polynucleotide encoding an Fc polypeptide described herein operably linked to a promoter for expression of such sequences in the host cell. In certain embodiments, vectors encoding both the first and second Fc polypeptide of a heterodimeric protein, individually, can be co-expressed in the host cell for expression of the entire heterodimeric protein, as detailed below. In certain embodiments, a host cell contains a vector comprising a polynucleotide encoding both the first and second Fc polypeptide of a heterodimeric protein described herein. In specific embodiments, a host cell contains two different vectors, a first vector comprising a polynucleotide encoding a first Fc polypeptide of a heterodimeric protein described herein and a second vector comprising a polynucleotide encoding a second Fc polypeptide of a heterodimeric protein. In certain embodiments, a host cell comprises the following four vectors: a first vector comprising a polynucleotide encoding a first antibody heavy chain of a first half-antibody of a heterodimeric protein described herein; a second vector comprising a polynucleotide encoding a second antibody heavy chain of a second half-antibody of a heterodimeric protein described herein; a third vector comprising a polynucleotide encoding a first antibody light chain of a first half-antibody of a heterodimeric protein described herein; and a fourth vector comprising a polynucleotide encoding a second antibody light chain of a second half-antibody of a heterodimeric protein described herein. In certain embodiments, vectors encoding the first antibody heavy chain of a first half-antibody, the second antibody heavy chain of a second half-antibody, the first antibody light chain of a first half-antibody, and the second antibody light chain of a second half-antibody, individually, can be co-expressed in the host cell to produce the heterodimeric protein.

[00109] In other embodiments, a first host cell comprises a first vector comprising a polynucleotide encoding a first Fc polypeptide of a heterodimeric protein described herein, and a second host cell comprises a second vector comprising a polynucleotide encoding a second Fc polypeptide of a heterodimeric protein described herein. In specific embodiments, a first Fc polypeptide expressed by a first cell associates with a second Fc polypeptide of a second cell to form a heterodimeric protein described herein. In certain embodiments, a first host cell comprises a first vector comprising a polynucleotide encoding a first antibody heavy chain of a first half-

antibody of a heterodimeric protein described herein and a second vector comprising a polynucleotide encoding a first antibody light chain of a first half-antibody of a heterodimeric protein described herein, and a second host cell comprises a third vector comprising a polynucleotide encoding a second antibody heavy chain of a second half-antibody of a heterodimeric protein described herein and a fourth vector comprising a polynucleotide encoding a second antibody light chain of a second half-antibody of a heterodimeric protein described herein. In certain embodiments, a first half-antibody expressed by a first cell associates with a second half-antibody of a second cell to form a heterodimeric protein described herein. In certain embodiments, provided herein is a population of host cells comprising such first host cell and such second host cell.

[00110] A variety of host-expression vector systems can be utilized to express Fc polypeptides described herein (see, e.g., U.S. Patent No. 5,807,715, which is herein incorporated by reference in its entirety). Such host-expression systems represent vehicles by which the coding sequences of interest can be produced and subsequently purified, but also represent cells which can, when transformed or transfected with the appropriate nucleotide coding sequences, express heterodimeric protein molecules described herein *in situ*. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli* and *B. subtilis*) transformed with, e.g., recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing heterodimeric protein coding sequences; yeast (e.g., *Saccharomyces Pichia*) transformed with, e.g., recombinant yeast expression vectors containing heterodimeric protein coding sequences; insect cell systems infected with, e.g., recombinant virus expression vectors (e.g., baculovirus) containing heterodimeric protein coding sequences; plant cell systems (e.g., green algae such as *Chlamydomonas reinhardtii*) infected with, e.g., recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with, e.g., recombinant plasmid expression vectors (e.g., Ti plasmid) containing heterodimeric protein coding sequences; or mammalian cell systems (e.g., COS (e.g., COS1 or COS), CHO, BHK, MDCK, HEK 293, NS0, PER.C6, VERO, CRL7030, HsS78Bst, HeLa, and NIH 3T3, HEK-293T, HepG2, SP210, R1.1, B-W, L-M, BSC1, BSC40, YB/20 and BMT10 cells) harboring, e.g., recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). In a specific embodiment, cells for expressing heterodimeric

proteins described herein are Chinese hamster ovary (CHO) cells, for example CHO cells from the CHO GS System™ (Lonza). In a particular embodiment, cells for expressing heterodimeric proteins described herein are human cells, e.g., human cell lines. In a specific embodiment, a mammalian expression vector is pOptiVEC™ or pcDNA3.3. In a particular embodiment, bacterial cells such as *Escherichia coli*, or eukaryotic cells (e.g., mammalian cells) are used for the expression of heterodimeric proteins. For example, mammalian cells such as CHO cells, in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for proteins, such as antibodies (Foecking MK & Hofstetter H (1986) Gene 45: 101-5; and Cockett MI et al., (1990) Biotechnology 8(7): 662-7, each of which is herein incorporated by reference in its entirety). In certain embodiments, heterodimeric proteins described herein are produced by CHO cells or NS0 cells. In a specific embodiment, the expression of nucleotide sequences encoding heterodimeric proteins described herein is regulated by a constitutive promoter, inducible promoter or tissue specific promoter.

[00111] In bacterial systems, a number of expression vectors can be advantageously selected depending upon the use intended for the heterodimeric protein being expressed. For example, when a large quantity of such protein is to be produced for the generation of pharmaceutical compositions of heterodimeric proteins, vectors which direct the expression of high levels of fusion protein products that are readily purified can be desirable. Such vectors include, but are not limited to, the *E. coli* expression vector pUR278 (Ruether U & Mueller-Hill B (1983) EMBO J 2: 1791-1794), in which the protein coding sequence can be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye S & Inouye M (1985) Nuc Acids Res 13: 3101-3109; Van Heeke G & Schuster SM (1989) J Biol Chem 24: 5503-5509); and the like, all of which are herein incorporated by reference in their entireties. For example, pGEX vectors can also be used to express foreign polypeptides as fusion proteins with glutathione 5-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

[00112] In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV), for example, can be used as a vector to express foreign genes. The virus grows in *Spodoptera*

frugiperda cells. The protein coding sequence can be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

[00113] In mammalian host cells, a number of viral-based expression systems can be utilized. In cases where an adenovirus is used as an expression vector, the protein coding sequence of interest can be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene can then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the heterodimeric protein in infected hosts (e.g., see Logan J & Shenk T (1984) PNAS 81(12): 3655-9, which is herein incorporated by reference in its entirety). Specific initiation signals can also be required for efficient translation of inserted protein coding sequences. These signals include the ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression can be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see, e.g., Bitter G et al., (1987) Methods Enzymol. 153: 516-544, which is herein incorporated by reference in its entirety).

[00114] In addition, a host cell strain can be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products can be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product can be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, Hela, MDCK, HEK 293, NIH 3T3, W138, BT483, Hs578T, HTB2, BT2O and T47D, NS0 (a murine myeloma cell line that does not endogenously produce any immunoglobulin chains), CRL7030, COS (e.g., COS1 or COS), PER.C6, VERO, HsS78Bst,

HEK-293T, HepG2, SP210, R1.1, B-W, L-M, BSC1, BSC40, YB/20, BMT10 and HsS78Bst cells. In certain embodiments, heterodimeric proteins described herein are produced in mammalian cells, such as CHO cells.

[00115] In a specific embodiment, the heterodimeric proteins described herein have reduced fucose content or no fucose content. Such proteins can be produced using techniques known to one skilled in the art. For example, the Fc polypeptides described herein can be expressed in cells deficient or lacking the ability of to fucosylate. In a specific example, cell lines with a knockout of both alleles of α 1,6-fucosyltransferase can be used to produce Fc polypeptides with reduced fucose content. The Potelligent® system (Lonza) is an example of such a system that can be used to produce Fc polypeptides with reduced fucose content.

[00116] For long-term, high-yield production of recombinant proteins, stable expression cells can be generated. For example, cell lines which stably express Fc polypeptides described herein can be engineered. In specific embodiments, a cell provided herein stably expresses a first Fc polypeptide and a second Fc polypeptide which associate to form a heterodimeric protein described herein. In certain embodiments, a first cell provided herein stably expresses a first Fc polypeptide and second cell provided herein stably expresses a second Fc polypeptide. In certain embodiments, a first Fc polypeptide expressed by a first cell associates with a second Fc polypeptide of a second cell to form a heterodimeric protein described herein.

[00117] In certain aspects, rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA/polynucleotide, engineered cells can be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method can advantageously be used to engineer cell lines which express Fc polypeptides described herein. Such engineered cell lines can be particularly useful in screening and evaluation of compositions that interact directly or indirectly with the Fc polypeptides.

[00118] A number of selection systems can be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler M et al., (1977) Cell 11(1): 223-32), hypoxanthineguanine

phosphoribosyltransferase (Szybalska EH & Szybalski W (1962) PNAS 48(12): 2026-2034) and adenine phosphoribosyltransferase (Lowy I et al., (1980) Cell 22(3): 817-23) genes in tk-, hgprt- or aprt-cells, respectively, all of which are herein incorporated by reference in their entireties. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler M et al., (1980) PNAS 77(6): 3567-70; O'Hare K et al., (1981) PNAS 78: 1527-31); gpt, which confers resistance to mycophenolic acid (Mulligan RC & Berg P (1981) PNAS 78(4): 2072-6); neo, which confers resistance to the aminoglycoside G-418 (Wu GY & Wu CH (1991) Biotherapy 3: 87-95; Tolstoshev P (1993) Ann Rev Pharmacol Toxicol 32: 573-596; Mulligan RC (1993) Science 260: 926-932; and Morgan RA & Anderson WF (1993) Ann Rev Biochem 62: 191-217; Nabel GJ & Felgner PL (1993) Trends Biotechnol 11(5): 211-5); and hygromycin (Santerre RF et al., (1984) Gene 30(1-3): 147-56), all of which are herein incorporated by reference in their entireties. Methods commonly known in the art of recombinant DNA technology can be routinely applied to select the desired recombinant clone and such methods are described, for example, in Ausubel FM et al., (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); Kriegler M, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli NC et al., (eds.), Current Protocols in Human Genetics, John Wiley & Sons, NY (1994); Colbère-Garapin F et al., (1981) J Mol Biol 150: 1-14, all of which are herein incorporated by reference in their entireties.

[00119] The expression levels of protein can be increased by vector amplification (for a review, see Bebbington CR & Hentschel CCG, The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning, Vol. 3 (Academic Press, New York, 1987), which is herein incorporated by reference in its entirety). When a marker in the vector system expressing an Fc polypeptide is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the Fc polypeptide gene, production of the Fc polypeptide will also increase (Crouse GF et al., (1983) Mol Cell Biol 3: 257-66, which is herein incorporated by reference in its entirety).

[00120] The host cell can be co-transfected with two or more expression vectors described herein, the first vector encoding a first Fc polypeptide and the second vector encoding a second Fc polypeptide. The two vectors can contain identical selectable markers which enable equal

expression of first and second Fc polypeptides. The host cells can be co-transfected with different amounts of the two or more expression vectors. For example, host cells can be transfected with any one of the following ratios of a first expression vector and a second expression vector: about 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:12, 1:15, 1:20, 1:25, 1:30, 1:35, 1:40, 1:45, or 1:50.

[00121] Alternatively, a single vector can be used which encodes, and is capable of expressing, both the first and second Fc polypeptides of a heterodimeric protein. The coding sequences for the first and second Fc polypeptides can comprise cDNA or genomic DNA. The expression vector can be monocistronic or multicistronic. A multicistronic nucleic acid construct can encode 2, 3, 4, 5, 6, 7, 8, 9, 10 or more genes/nucleotide sequences, or in the range of 2-5, 5-10, or 10-20 genes/nucleotide sequences. For example, a bicistronic nucleic acid construct can comprise, in the following order, a promoter, a first gene (e.g., first Fc polypeptide of a heterodimeric protein described herein), and a second gene and (e.g., second Fc polypeptide of a heterodimeric protein described herein). In such an expression vector, the transcription of both genes can be driven by the promoter, whereas the translation of the mRNA from the first gene can be by a cap-dependent scanning mechanism and the translation of the mRNA from the second gene can be by a cap-independent mechanism, e.g., by an IRES.

[00122] Once a heterodimeric protein or Fc polypeptide described herein has been produced by recombinant expression, it can be purified by any method known in the art for protein purification, for example, by chromatography (e.g., ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. Further, the heterodimeric proteins and Fc polypeptides described herein can be fused to heterologous polypeptide sequences described herein or otherwise known in the art to facilitate purification.

[00123] In specific embodiments, a heterodimeric protein or Fc polypeptide described herein is isolated or purified. Generally, an isolated protein is one that is substantially free of other proteins. For example, in a particular embodiment, a preparation of a heterodimeric protein or Fc polypeptides described herein is substantially free of cellular material and/or chemical precursors. The language “substantially free of cellular material” includes preparations of a protein in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly produced. Thus, a protein that is substantially free of cellular material includes preparations of protein having less than about 30%, 20%, 10%, 5%, 2%, 1%, 0.5%, or 0.1% (by

dry weight) of heterologous protein (also referred to herein as a “contaminating protein”) and/or variants of a protein, for example, different post-translational modified forms of a protein or other different versions of a protein (e.g., protein fragments). When the protein is recombinantly produced, it is also generally substantially free of culture medium, i.e., culture medium represents less than about 20%, 10%, 2%, 1%, 0.5%, or 0.1% of the volume of the protein preparation. When the protein is produced by chemical synthesis, it is generally substantially free of chemical precursors or other chemicals, i.e., it is separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. Accordingly, such preparations of the protein have less than about 30%, 20%, 10%, or 5% (by dry weight) of chemical precursors or compounds other than the protein of interest. In a specific embodiment, heterodimeric proteins and Fc polypeptides described herein are isolated or purified.

[00124] Heterodimeric proteins and Fc polypeptides described herein can be produced by any method known in the art for the synthesis of proteins, for example, by chemical synthesis or by recombinant expression techniques. The methods described herein employ, unless otherwise indicated, conventional techniques in molecular biology, microbiology, genetic analysis, recombinant DNA, organic chemistry, biochemistry, PCR, oligonucleotide synthesis and modification, nucleic acid hybridization, and related fields within the skill of the art. These techniques are described, for example, in the references cited herein and are fully explained in the literature. See, e.g., Maniatis T et al., (1982) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press; Sambrook J et al., (1989), *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press; Sambrook J et al., (2001) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel FM et al., *Current Protocols in Molecular Biology*, John Wiley & Sons (1987 and annual updates); *Current Protocols in Immunology*, John Wiley & Sons (1987 and annual updates) Gait (ed.) (1984) *Oligonucleotide Synthesis: A Practical Approach*, IRL Press; Eckstein (ed.) (1991) *Oligonucleotides and Analogues: A Practical Approach*, IRL Press; Birren B et al., (eds.) (1999) *Genome Analysis: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, all of which are herein incorporated by reference in their entireties.

6. EXAMPLES

[00125] The examples are offered by way of illustration and not by way of limitation.

6.1 Example 1: Synthesis and Heterodimerization of Fc Polypeptides

[00126] This example describes the synthesis and heterodimerization of Fc polypeptides specific for Target 1 or Target 2 (two different antigens present on the surface of human T cells).

6.1.1 Fc polypeptide synthesis

[00127] Twelve Fc polypeptides (each comprising a half-antibody specific for either Target 1 or Target 2) were expressed in CHO cells and purified using Protein A affinity chromatography (GE Healthcare). The binding specificity of the antigen binding portion, and the amino acid sequence of the heavy chain constant region, for each of the twelve Fc polypeptides is described in Table 3.

Table 3: Fc polypeptides

Fc polypeptide #	Antigen specificity and Fc mutation(s)	SEQ ID NO of heavy chain constant region sequence*
1	Target 1 T366W	22
2	Target 1 T366S/L368A/Y407V	30
3	Target 1 S239D/A330L/I332E/ T366W	24
4	Target 1 S239D/A330L/I332E/ T366S/L368A/Y407V	32
5	Target 1 S239D/ T366S/L368A/Y407V	36
6	Target 1 wild-type IgG1	14
7	Target 2 T366W	22
8	Target 2 T366S/L368A/Y407V	30
9	Target 2 S239D/A330L/I332E/ T366W	24
10	Target 2 S239D/A330L/I332E/ T366S/L368A/Y407V	32
11	Target 2 S239D/ T366S/L368A/Y407V	36

12	Target 2 wild-type IgG1	14
----	-------------------------	----

*The nucleic acid coding sequence for each of these heavy chain constant regions includes a lysine at the C-terminus.

[00128] Protein expression levels for Fc polypeptide #s 4, 5, 2, 10, 11, and 8 were measured and compared. As shown in Figure 1, Fc polypeptides 4 and 10 (which contained both S239D/A330L/I332E mutations and T366S/L368A/Y407V mutations) were expressed at negligible levels relative to the other Fc polypeptides tested.

6.1.2 Heterodimerization of Fc polypeptides

[00129] The Fc polypeptides set forth in Table 3 were heterodimerized to form the heterodimeric proteins described in Table 4. Briefly, the first and second Fc polypeptides indicated in Table 4 were mixed in equimolar amounts in the presence of 50 mM of reductant (2-MEA) for at least 2 hours to reduce heavy chain interchain disulphide bonds. The mixtures of Fc polypeptides were then buffer-exchanged into reoxidation buffer (10 mM sodium citrate pH 6.0, 115 mM NaCl) using desalting PD-10 columns to remove the reductant and incubated at room temperature for 24 hours to facilitate dimerization of the first and second Fc polypeptides. The resultant Fc polypeptide mixtures were then buffer-exchanged into storage buffer (10 mM histidine pH 6 and 115 mM NaCl). Purity and quality were determined by SDS-PAGE and dimer formation and percent heterodimerization was assessed by absolute size-exclusion chromatography (ASEC).

Table 4: Heterodimeric proteins

Name	First Fc polypeptide	Second Fc polypeptide
BA111	Fc polypeptide #1	Fc polypeptide #2
BA112	Fc polypeptide #3	Fc Polypeptide #2
BA113	Fc polypeptide #3	Fc polypeptide #5
BA114	Fc polypeptide #3	Fc polypeptide #4
BA115	Fc polypeptide #7	Fc polypeptide #8
BA116	Fc polypeptide #9	Fc polypeptide #8

BA117	Fc polypeptide #9	Fc polypeptide #11
BA118	Fc polypeptide #9	Fc polypeptide #10

6.1.3 Thermal stability

[00130] The thermal stability of heterodimeric protein BA111, BA112, BA113, BA114, BA115, BA116, BA117, and BA118 was assessed. 1µl of Sypro Orange Fluorescent Dye (final Sypro concentration at 5x) was added to 4µg of protein diluted in PBS. The Sypro Orange fluorescence was analyzed on a Thermal Cycler (Biorad CFX96 Real-Time System C1000 PCR Detection System) using a thermal ramp starting at 10°C to 95°C and the protein thermal shifts were analyzed on the CFX Maestro software. Bar charts were created in prism.

[00131] Figure 2A shows the melting temperature for anti-Target 1 heterodimeric proteins BA111, BA112, BA113, and BA114. The melting temperature of BA114 is lower than BA111, BA112, or BA113.

[00132] Figure 2B shows the melting temperature for anti-Target 2 heterodimeric proteins BA115, BA116, BA117, and BA118. The melting temperature of BA118 is lower than BA115, BA116, or BA117.

6.2 Example 2: Target Binding

[00133] This example demonstrates the ability of the heterodimeric proteins set forth in Table 4 to bind to their intended targets.

6.2.1 Target 1

[00134] The ability of heterodimeric proteins BA111, BA112, BA113, BA114, homodimeric protein BA119 (WT IgG₁), and an IgG₁ isotype control antibody to bind to Target 1 was assessed.

[00135] Briefly, a frozen aliquot of Jurkat cells engineered to express human Target 1 was thawed at 37°C and cultured overnight in RPMI media supplemented with 10% fetal bovine serum (FBS) at 37°C and 5% CO₂. Cells were counted and their viability assessed using a Muse apparatus (Luminex Corp.) by mixing a 20 µl aliquot of cells with 380 µl of viability dye. Cells were then pelleted by centrifugation at 1500 rpm for five minutes and resuspended to a final concentration of 1×10^6 cells/mL in 1X phosphate buffer saline (PBS) supplemented with 2% FBS (FACS buffer). Cells were seeded in a 96-well U-bottom tissue culture plate at a density of 1×10^5

cells per well and washed twice with FACS buffer.

[00136] Heterodimeric proteins were serially diluted 1:10 in FACS buffer for a total of 8 working dilutions ranging from 50 µg/ml to 0.000005 µg/ml. Cells were resuspended in 50 µl of the heterodimeric protein solution, and incubated for 30 minutes at 4°C.

[00137] To detect heterodimeric protein binding, cells were washed twice with cold FACS Buffer and resuspended in FACS Buffer containing fluorescein isothiocyanate (FITC)-labeled goat anti-human IgG (H+L) secondary antibody at a 1:200 final dilution and live/dead staining solution at a 1:1000 final dilution. Cells were then incubated for 30 minutes at 4°C, washed twice with cold FACS Buffer, and analyzed by flow cytometry (BD LSR Fortessa Flow Cytometer). The data was analyzed using FlowJo (Version 10, FLOWJO) software by sequentially gating the FSC-A vs. SSC-A, SSC-H vs SSC-A, and SSC-A vs. live-dead. Mean fluorescence intensity (MFI) values for FITC staining were calculated, and the data was plotted using GraphPad Prism software (Version 7, GraphPad Software Inc.).

[00138] As shown in Figure 3, BA111, BA112, BA113, BA114, and BA119 showed potent and comparable binding to Target 1-expressing cells.

6.2.2 Target 2

[00139] The ability of heterodimeric proteins BA115, BA116, BA117, BA118, homodimeric protein BA120 (WT IgG₁), and an IgG₁ isotype control antibody to bind Target 2 was assessed.

[00140] Briefly, a frozen aliquot of CHO cells engineered to express Target 2 was thawed at 37°C and cultured overnight in F-12 media supplemented with 10% fetal bovine serum (FBS) at 37°C and 5% CO₂. Cells were counted and their viability assessed using a Vi-XCell apparatus. Cells were then pelleted by centrifugation at 1500 rpm for five minutes and resuspended to a final concentration of 1×10^6 cells/mL in 1X phosphate buffer saline (PBS) supplemented with 2% FBS (FACS buffer). Cells were seeded in a 96-well U-bottom tissue culture plate at a density of 1×10^5 cells per well and washed twice with FACS buffer.

[00141] Heterodimeric proteins were serially diluted 1:3 in FACS buffer for a total of 8 working dilutions ranging from 30 µg/ml to 0.013717 µg/ml. Cells were resuspended in 50 µl of the heterodimeric protein solution, and incubated for 30 minutes at 4°C.

[00142] To detect heterodimeric protein binding, cells were washed twice with cold FACS Buffer and resuspended in FACS Buffer containing fluorescein isothiocyanate (FITC)-labeled goat anti-human IgG (H+L) secondary antibody at a 1:200 final dilution and live/dead staining solution

at a 1:1000 final dilution. Cells were then incubated for 30 minutes at 4°C, washed twice with cold FACS Buffer, and analyzed by flow cytometry (BD LSR Fortessa Flow Cytometer). The data was analyzed using the FlowJo software by sequentially gating the FSC-A vs. SSC-A, SSC-H vs SSC-A, and SSC-A vs. live-dead. Mean fluorescence intensity (MFI) values for FITC staining were calculated, and the data was plotted using GraphPad Prism software.

[00143] As shown in Figure 4, BA115, BA116, BA117, BA118, and BA120 showed potent and comparable binding to Target 2-expressing cells.

6.3 Example 3: Target Blockade

[00144] This example demonstrates the ability of the heterodimeric proteins set forth in Table 4 to block signaling in cells expressing their intended target.

6.3.1 Target 1

[00145] The ability of heterodimeric proteins BA111, BA112, BA113, BA114, homodimeric protein BA119 (WT IgG₁), and an IgG₁ isotype control antibody to block signaling by binding Target 1 was assessed using a Jurkat reporter assay.

[00146] Briefly, a human T cell line (Jurkat) engineered to express human Target 1 with a luciferase reporter driven by a native promoter that can respond to both TCR activation and inhibitory co-receptor signaling that suppresses activation (Promega) was plated in a 96 well flat-bottom white plate according to the manufacturer's protocol and treated with a dose-titration of BA111, BA112, BA113, BA114, BA119, and an IgG₁ isotype control antibody, serially diluted 1-to-2.5 in culture media from 50 µg/ml to 0.015 µg/ml. To assess the functional activity of the indicated heterodimeric proteins, CHO-K1 cells engineered to express the natural ligand of Target 1 and an engineered cell surface protein designed to activate the T cell receptor (TCR) complex in an antigen-independent manner were co-cultured with the heterodimeric protein-treated Jurkat reporter cell line for 6 hours at 37°C and 5% CO₂. To assess the ability of the heterodimeric proteins to block the interaction of Target 1 with its natural ligand and enhance T cell activation gene activity, luciferase expression was quantified using Bio-Glo™ reagent and an Envision plate-reading luminometer.

[00147] As shown in Figure 5, co-culture of the cell lines resulted in engagement of the inhibitory co-receptor of Target 1 (expressed on Jurkat cells) with its natural ligands CD80 and CD86 (expressed on Raji cells), which inhibited T cell activation, as shown by a lack of luciferase

expression. This inhibition was relieved upon addition of increasing concentrations of BA111, BA112, BA113, BA114, or the homodimeric protein BA119. BA111, BA112, BA113, BA114 and BA119 were functionally comparable at enhancing T cell activation, as determined by IL-2 reporter gene activity.

6.3.2 Target 2

[00148] The ability of heterodimeric proteins BA115, BA116, BA117, BA118, homodimeric protein BA120 (WT IgG₁), and an IgG₁ isotype control antibody to block signaling by binding Target 2 was assessed using a Jurkat reporter assay.

[00149] Briefly, a human T cell line (Jurkat) that endogenously expresses the inhibitory co-receptor of Target 2 was engineered to constitutively express cell surface Target 2 and a luciferase reporter gene driven by an IL-2 promoter (Promega). Cells were plated in a 96 well flat-bottom white plate according to the manufacturer's protocol and treated with a dose-titration of the indicated anti-Target 2 heterodimeric proteins or an isotype control IgG₁ antibody. Heterodimeric proteins were serially diluted 1:2.5 in culture media with concentrations ranging from 50 µg/ml to 0.015 µg/ml. An antigen presenting cell line (Raji) that endogenously expresses the natural ligands of Target 2, and was engineered to express a proprietary T cell activator, was prepared according to the manufacturer's instructions and co-cultured with the heterodimeric protein-treated Jurkat cells for 6 hours at 37°C and 5% CO₂. To assess the ability of the heterodimeric proteins to block Target 2 interactions and enhance IL-2 reporter gene activity, luciferase expression was quantified using Bio-Glo™ reagent and an Envision plate-reading luminometer.

[00150] As shown in Figure 6, co-culture of the two cell lines resulted in engagement of the inhibitory co-receptor of Target 2 (expressed on Jurkat cells) with its natural ligands (expressed on Raji cells), which inhibited T cell activation, as shown by a lack of luciferase expression. This inhibition was relieved upon addition of increasing concentrations of BA115, BA116, BA117, BA118, or the homodimeric protein BA120. BA115, BA116, BA117, BA118, and BA120 were functionally comparable at enhancing T cell activation, as determined by IL-2 reporter gene activity.

6.4 Example 4: SEA Stimulation Assay

[00151] This example demonstrates the ability of heterodimeric proteins to elicit IL-2 secretion by SEA-stimulated PBMCs.

6.4.1 Target 1

[00152] The ability of heterodimeric proteins specific for Target 1 to elicit IL-2 secretion by SEA-stimulated PBMCs was investigated.

[00153] Briefly, a 5× concentrated intermediate stock of heterodimeric protein sufficient for three replicates per donor was prepared in 1.2 mL bullet tubes. First, 420 µL of 500 µg/mL of each heterodimeric protein was prepared in R10 media. Heterodimeric proteins were then serially diluted 1-to-10 for a total of 8 dilutions and 20 µL of heterodimeric protein mixture was then added to corresponding wells of a round-bottom 96-well plate. Frozen aliquots of human PBMCs were retrieved from liquid nitrogen and immediately thawed in 37° C water. Cells were transferred to 9 mL of pre-warmed R10 media and immediately centrifuged at 2000 rpm for two minutes. Cells were then counted, and viability was assessed. Cells were centrifuged at 2000 rpm for two minutes and resuspended.

[00154] An intermediate stock concentration of SEA was made by diluting 10 µL of 10 µg/mL of SEA in 90 µL of R10 to make an intermediate concentration of 1 µg/mL. To stimulate the cells, 35 µL of the 1 µg/mL intermediate stock of SEA was added to 28 mL of cells. 80 µL of cells and SEA mixture was added into corresponding wells and incubated in a humidified chamber at 37° C and 5% CO₂ for four days. A total of 0.1×10^6 cells/well and a final concentration of 1 ng/mL of SEA was used.

[00155] After four days of incubation, plates were removed from the incubator, gently agitated by hand, and then centrifuged for two minutes at 2000 rpm. 5 µL of the supernatant was transferred to a 384-well AlphaLISA plate (Perkin Elmer) for cytokine analysis. AlphaLISA kits were used for the measurements of IL-2 in accordance with manufacturer instructions. Briefly, assay buffer was prepared by adding 2.5 mL of 10× AlphaLISA Immunoassay Buffer to 22.5 mL water. Human IL-2 analyte was used to prepare a standard dilution in accordance with manufacturer instructions. A mixture of 1.6× AlphaLISA anti-IL-2 acceptor beads and biotinylated antibody anti-IL-2 mix was prepared in assay buffer. 8 µL was added to each well and incubated in darkness at room temperature, rotating at 500 rpm for 90 minutes. A 2.3× streptavidin donor bead intermediate stock was prepared in assay buffer. 10 µL was added to each well and incubated in darkness at room temperature, rotating at 500 rpm for 20 minutes. AlphaLISA plates were briefly centrifuged at 2000 rpm. Relative light units (RLU) were measured using the AlphaScreen protocol on an EnVision Plate Reader.

[00156] As shown in Figures 7A-7P, BA113 potently enhanced IL-2 secretion in a dose-dependent manner that was comparable to Reference Homodimeric Protein 2, also specific for Target 1. BA113 demonstrated superior functional activity compared BA112 and BA111. BA111 did not induce significant levels of IL-2 secretion over cells treated with a homodimeric isotype control protein, which comprises S239D/A330L/I332E mutations (“Fc enhanced”), and was used as an isotype control. BA114 showed an apparent reduced potency in enhancing IL-2 secretion compared to BA113. The results presented in Figures 7A-7P were obtained using PBMCs from 3 different donors, Donor 1 (Figures 7A-7D and Figures 7I-7L), Donor 2 (Figures 7E-7H), and Donor 3 (Figures 7M-7P).

6.4.2 Target 2

[00157] The ability of heterodimeric proteins specific for Target 2 to elicit IL-2 secretion by SEA-stimulated PBMCs was investigated.

[00158] Experiments were performed as described in Example 6.4.1 above utilizing BA115, BA116, BA117, BA118, and Reference Homodimeric Protein 1. A homodimeric isotype protein, which comprises S239D/A330L/I332E mutations (“Fc enhanced”), was used as an isotype control.

[00159] As shown in Figures 8A-8X, BA117 potently enhanced IL-2 secretion in a dose-dependent manner and demonstrated superior functional activity compared BA116 and BA115 and Reference Homodimeric Protein 1, also specific for Target 2. BA115 demonstrated significantly reduced potency compared to BA117, BA118 or BA116. BA115 and BA118 variant showed comparable functional activity at enhancing IL-2 secretion from SEA-stimulated PBMC donors.

6.5 Example 5: Fc Binding

6.5.1 FcγRIIIA (CD16) binding

6.5.1.1 Target 1

[00160] The ability of BA111, BA112, BA113, and BA114 to bind FcγRIIIA was assessed using a cell binding assay.

[00161] Briefly, CHO cells expressing hFcγRIIIA (V/V) or hFcγRIIIA (F/F) were thawed from frozen and resuspended in 5ml FACS buffer (DPBS, BSA 0.5%, Azide 0.05%) at a density of 4×10^6 cells/ml. The cells were dispensed in a 96-well U-bottom tissue culture plate at a density of

2x10⁵ cells/well and were then incubated for 45 minutes at 4°C with a series dilution of BA111, BA112, BA113, and BA114 at concentrations from 60 µg/mL to 7 ng/mL diluted in FACS buffer. For antibody staining, the cells were washed twice with cold FACS buffer and re-suspended in FACS buffer containing goat anti-human IgG-PE (F(ab)2 anti-Fc) (JIR, Cat #109-116-098) at 1:800 dilution. After a 45-minute incubation at 4°C, the cells were washed twice with cold FACS buffer, and the cells were analyzed by flow cytometry (BD LSR Fortessa Flow Cytometer). The data were analyzed by the FlowJo software by sequentially gating on the FSC-A vs. SSC-A, SSC-H vs SSC-A, and Count vs PE. Geometric Mean fluorescence intensity (gMFI) values were calculated, and the data were plotted by GraphPad Prism software. Data is from three separate experiments; error bar represent standard error of the mean.

[00162] As shown in Figures 9A and 9B, BA112, BA113, and BA114 bind to the FcγRIIIA V/V (Figure 9A) and F/F (Figure 9B) expressed on CHO cells. BA113 demonstrates enhanced binding FcγRIIIA V/V (Figure 9A) and F/F (Figure 9B) as compared to BA111.

6.5.1.2 Target 2

[00163] The ability of BA115, BA116, BA117, and BA118 to bind FcγRIIIA was assessed using a cell binding assay.

[00164] The experiment was carried out as described in section 6.5.1.1 except that heterodimeric proteins BA115, BA116, BA117, and BA118 were used at concentrations from 60 µg/mL to 7 ng/mL. Data is from three experiments, error bar represent standard error of the mean.

[00165] As shown in Figures 10A and 10B, BA116, BA117, and BA118 bind to the FcγRIIIA V/V (Figure 10A) and F/F (Figure 10B) expressed on CHO cells. BA117 demonstrates enhanced binding to FcγRIIIA V/V (Figure 10A) and F/F (Figure 10B) as compared to BA115.

6.5.2 Other Fc receptors

[00166] The ability of BA112, BA113, BA114, BA115, BA116, BA117, and BA118 to bind to FcγRI, FcγRIIa H/H, FcγRIIa R/R, and FcγRIIb was also assessed using cell binding assays and no meaningful differences were observed.

6.5.3 FcγRIIIA (CD16) binding for additional heterodimeric proteins

[00167] This example describes the synthesis, heterodimerization, and Fc receptor binding of additional Fc polypeptides specific for Target 1 or Target 2 (two different antigens present on the surface of human T cells).

[00168] Additional Fc polypeptides (each comprising a half-antibody specific for either Target 1 or Target 2) were expressed in CHO cells and purified using Protein A affinity chromatography (GE Healthcare). The binding specificity of the antigen binding portion, and the amino acid sequence of the heavy chain constant region, for each of the twelve Fc polypeptides is described in Table 5.

Table 5: Fc polypeptides

Fc polypeptide #	Antigen specificity and Fc mutation(s)	SEQ ID NO of heavy chain constant region sequence*
13	Target 1 T366W/S239D/A330L	68
14	Target 1 T366W/S239D/I332E	26
15	Target 1 T366W/A330L/I332E	75
16	Target 1 T366W/S239D	28
17	Target 1 T366W/A330L	69
18	Target 1 T366W/I332E	70
19	Target 1 T366S/L368A/Y407V/S239D/A330L	71
20	Target 1 T366S/L368A/Y407V/A330L/I332E	72
21	Target 1 T366S/L368A/Y407V/S239D/I332E	34
22	Target 1 T366S/L368A/Y407V/A330L	73
23	Target 1 T366S/L368A/Y407V/I332E	74
24	Target 2 T366W/S239D/A330L	68
25	Target 2 T366W/S239D/I332E	26

26	Target 2 T366W/S239D	28
27	Target 2 T366W/A330L	69
28	Target 2 T366W/I332E	70
29	Target 2 T366S/L368A/Y407V/S239D/A330L	71
30	Target 2 T366S/L368A/Y407V/A330L/I332E	72
31	Target 2 T366S/L368A/Y407V/S239D/I332E	34
32	Target 2 T366S/L368A/Y407V/A330L	73
33	Target 2 T366S/L368A/Y407V/I332E	74

[00169] The Fc polypeptides set forth in Tables 3 and/or 5 were heterodimerized to form the monospecific heterodimeric proteins described in Table 6. Heterodimerization was performed as described in Example 6.1.2.

Table 6: Heterodimeric proteins

Name	First Fc polypeptide	Second Fc polypeptide
BA115	Fc polypeptide #7	Fc polypeptide #8
BA116	Fc polypeptide #9	Fc Polypeptide #8
BA161	Fc polypeptide #24	Fc polypeptide #8
BA162	Fc polypeptide #25	Fc Polypeptide #8
BA163	Fc polypeptide #26	Fc polypeptide #8
BA164	Fc polypeptide #27	Fc polypeptide #8
BA165	Fc polypeptide #28	Fc polypeptide #8
BA166	Fc polypeptide #7	Fc polypeptide #29

BA167	Fc polypeptide #9	Fc polypeptide #29
BA168	Fc polypeptide #24	Fc polypeptide #29
BA169	Fc polypeptide #25	Fc polypeptide #29
BA170	Fc polypeptide #26	Fc polypeptide #29
BA171	Fc polypeptide #27	Fc polypeptide #29
BA172	Fc polypeptide #28	Fc polypeptide #29
BA173	Fc polypeptide #7	Fc polypeptide #30
BA174	Fc polypeptide #9	Fc polypeptide #30
BA175	Fc polypeptide #24	Fc polypeptide #30
BA176	Fc polypeptide #25	Fc polypeptide #30
BA177	Fc polypeptide #26	Fc polypeptide #30
BA178	Fc polypeptide #27	Fc polypeptide #30
BA179	Fc polypeptide #28	Fc polypeptide #30
BA180	Fc polypeptide #7	Fc polypeptide #31
BA181	Fc polypeptide #9	Fc polypeptide #31
BA182	Fc polypeptide #24	Fc polypeptide #31
BA183	Fc polypeptide #25	Fc polypeptide #31
BA184	Fc polypeptide #26	Fc polypeptide #31
BA185	Fc polypeptide #27	Fc polypeptide #31
BA186	Fc polypeptide #28	Fc polypeptide #31
BA187	Fc polypeptide #7	Fc polypeptide #11
BA117	Fc polypeptide #9	Fc polypeptide #11
BA188	Fc polypeptide #24	Fc polypeptide #11
BA189	Fc polypeptide #25	Fc polypeptide #11

BA190	Fc polypeptide #26	Fc polypeptide #11
BA191	Fc polypeptide #27	Fc polypeptide #11
BA192	Fc polypeptide #28	Fc polypeptide #11
BA193	Fc polypeptide #7	Fc polypeptide #32
BA194	Fc polypeptide #9	Fc polypeptide #32
BA195	Fc polypeptide #24	Fc polypeptide #32
BA196	Fc polypeptide #25	Fc polypeptide #32
BA197	Fc polypeptide #26	Fc polypeptide #32
BA198	Fc polypeptide #27	Fc polypeptide #32
BA199	Fc polypeptide #28	Fc polypeptide #32
BA200	Fc polypeptide #7	Fc polypeptide #33
BA201	Fc polypeptide #9	Fc polypeptide #33
BA202	Fc polypeptide #24	Fc polypeptide #33
BA203	Fc polypeptide #25	Fc polypeptide #33
BA204	Fc polypeptide #26	Fc polypeptide #33
BA205	Fc polypeptide #27	Fc polypeptide #33
BA206	Fc polypeptide #28	Fc polypeptide #33
BA111	Fc polypeptide #1	Fc polypeptide #2
BA112	Fc polypeptide #3	Fc polypeptide #2
BA207	Fc polypeptide #13	Fc polypeptide #2
BA208	Fc polypeptide #14	Fc polypeptide #2
BA209	Fc polypeptide #15	Fc polypeptide #2
BA210	Fc polypeptide #16	Fc polypeptide #2
BA211	Fc polypeptide #17	Fc polypeptide #2

BA212	Fc polypeptide #18	Fc polypeptide #2
BA213	Fc polypeptide #1	Fc polypeptide #19
BA214	Fc polypeptide #3	Fc polypeptide #19
BA215	Fc polypeptide #13	Fc polypeptide #19
BA216	Fc polypeptide #14	Fc polypeptide #19
BA217	Fc polypeptide #15	Fc polypeptide #19
BA218	Fc polypeptide #16	Fc polypeptide #19
BA219	Fc polypeptide #17	Fc polypeptide #19
BA220	Fc polypeptide #18	Fc polypeptide #19
BA221	Fc polypeptide #1	Fc polypeptide #20
BA222	Fc polypeptide #3	Fc polypeptide #20
BA223	Fc polypeptide #13	Fc polypeptide #20
BA224	Fc polypeptide #14	Fc polypeptide #20
BA225	Fc polypeptide #15	Fc polypeptide #20
BA226	Fc polypeptide #16	Fc polypeptide #20
BA227	Fc polypeptide #17	Fc polypeptide #20
BA228	Fc polypeptide #18	Fc polypeptide #20
BA229	Fc polypeptide #1	Fc Polypeptide #21
BA230	Fc polypeptide #3	Fc Polypeptide #21
BA231	Fc polypeptide #13	Fc Polypeptide #21
BA232	Fc polypeptide #14	Fc Polypeptide #21
BA233	Fc polypeptide #15	Fc Polypeptide #21
BA234	Fc polypeptide #16	Fc Polypeptide #21
BA235	Fc polypeptide #17	Fc Polypeptide #21

BA236	Fc polypeptide #18	Fc Polypeptide #21
BA237	Fc polypeptide #1	Fc polypeptide #5
BA113	Fc polypeptide #3	Fc polypeptide #5
BA238	Fc polypeptide #13	Fc polypeptide #5
BA239	Fc polypeptide #14	Fc polypeptide #5
BA240	Fc polypeptide #15	Fc polypeptide #5
BA241	Fc polypeptide #16	Fc polypeptide #5
BA242	Fc polypeptide #17	Fc polypeptide #5
BA243	Fc polypeptide #18	Fc polypeptide #5
BA244	Fc polypeptide #1	Fc polypeptide #22
BA245	Fc polypeptide #3	Fc polypeptide #22
BA246	Fc polypeptide #13	Fc polypeptide #22
BA247	Fc polypeptide #14	Fc polypeptide #22
BA248	Fc polypeptide #15	Fc polypeptide #22
BA249	Fc polypeptide #16	Fc polypeptide #22
BA250	Fc polypeptide #17	Fc polypeptide #22
BA251	Fc polypeptide #18	Fc polypeptide #22
BA252	Fc polypeptide #1	Fc polypeptide #23
BA253	Fc polypeptide #3	Fc polypeptide #23
BA254	Fc polypeptide #13	Fc polypeptide #23
BA255	Fc polypeptide #14	Fc polypeptide #23
BA256	Fc polypeptide #15	Fc polypeptide #23
BA257	Fc polypeptide #16	Fc polypeptide #23
BA258	Fc polypeptide #17	Fc polypeptide #23

BA259	Fc polypeptide #18	Fc polypeptide #23
-------	--------------------	--------------------

[00170] The ability of the heterodimeric proteins in Table 6 to bind Fc γ RIIIA F/F was assessed using a cell binding assay, as described in Example 6.5.1 with the exception that the detection antibody used for assessing the anti-target 1 heterodimeric proteins shown in Figure 11 and Table 7 was goat anti-human IgG-Alexa Fluor 488, Fc γ Fragment Specific (JIR, Cat# 109-546-098). The dilution range used in both Figure 11 and Figure 12 was 100 μ g/ml - 0 μ g/ml with a 1:4 stepwise dilution. In each case, a reference homodimeric protein containing S239D/A330L/I332E mutations ("Fc enhanced") was used for comparison.

[00171] The ability of the anti-target 1 heterodimeric proteins with various Fc polypeptides to bind to CHO cells expressing cell surface human Fc γ RIIIA F/F is shown in Figures 11A-11G. The level of heterodimeric protein binding to the cells, as assessed by the geometric mean fluorescence intensity (MFI), was plotted against the concentrations of heterodimeric protein incubated with the cells. The area under the curve for each heterodimeric protein is presented in Table 7.

[00172] The ability of the anti-target 2 heterodimeric proteins with various Fc polypeptides to bind to CHO cells expressing cell surface human Fc γ RIIIA F/F is shown in Figures 12A-12G. The level of heterodimeric protein binding to the cells, as assessed by the geometric mean fluorescence intensity (MFI), was plotted against the concentrations of heterodimeric protein incubated with the cells. The area under the curve for each heterodimeric protein is presented in Table 8.

Table 7: Area under the curve for heterodimeric proteins presented in Figures 11A-11G

Name	AUC
Reference homodimeric protein 3	400560
BA222	482384
BA214	480264
BA230	479341
BA232	440787

BA113	434339
BA224	341586
BA255	289244
BA245	276263
BA233	270566
BA226	249901
BA239	248715
BA216	248277
BA240	246156
BA217	242282
BA223	238873
BA253	236702
BA231	229864
BA236	224726
BA234	205394
BA254	196874
BA220	193500
BA257	188615
BA243	173798
BA215	169206
BA218	164197
BA225	155132
BA228	153773
BA256	147779

BA247	140591
BA238	139565
BA259	135178
BA221	129190
BA248	128792
BA241	109967
BA213	97090
BA235	95446
BA251	88508
BA227	84590
BA246	76963
BA249	69589
BA219	66111
BA258	60553
BA242	49501
BA229	48590
BA237	40479
BA252	28796
BA244	26352
BA111	22945
BA250	17687
BA209	12160
BA112	11542
BA208	8967

BA211	8941
BA207	8588
BA212	8440
BA210	8416

Table 8: Area under the curve for heterodimeric proteins presented in Figures 12A-12G

Name	AUC
Reference homodimeric protein 4	92261
BA181	409269
BA183	363045
BA201	298944
BA174	229726
BA186	226029
BA203	221615
BA182	213536
BA184	201835
BA117	201821
BA176	175408
BA167	175293
BA189	173119
BA169	163892
BA175	138038
BA204	136837

BA177	131142
BA172	128775
BA202	123520
BA168	110262
BA188	109496
BA170	100200
BA179	98624
BA180	90331
BA192	89857
BA206	83706
BA116	79878
BA190	78765
BA200	63320
BA185	63295
BA173	55475
BA162	50986
BA194	49928
BA165	46970
BA178	46437
BA163	41201
BA161	38733
BA196	37758
BA171	37697
BA187	31952

BA166	31226
BA205	30148
BA191	27189
BA199	18921
BA115	14042
BA195	12935
BA197	12766
BA164	11045
BA193	3647
BA198	3474

* * *

[00173] The invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications disclosed herein in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

[00174] All references (e.g., publications or patents or patent applications) cited herein are incorporated herein by reference in their entirety and for all purposes to the same extent as if each individual reference (e.g., publication or patent or patent application) was specifically and individually indicated to be incorporated by reference in its entirety for all purposes. Other embodiments are within the following claims.

WHAT IS CLAIMED:

1. A heterodimeric protein comprising a first Fc polypeptide and a second Fc polypeptide, wherein:
 - a) the first Fc polypeptide comprises aspartate, glutamate, and tryptophan at amino acid positions 239, 332, and 366, respectively; and
 - b) the second Fc polypeptide comprises aspartate, serine, alanine, and valine at amino acid positions 239, 366, 368, and 407, respectively, but does not comprise glutamate at amino acid position 332,wherein the amino acid positions are numbered according to the EU index.
2. The heterodimeric protein of claim 1, wherein the first Fc polypeptide further comprises leucine at amino acid position 330, wherein the amino acid positions are numbered according to the EU index.
3. The heterodimeric protein of claim 1 or 2, wherein the second Fc polypeptide does not comprise leucine at amino acid position 330, wherein the amino acid positions are numbered according to the EU index.
4. The heterodimeric protein of any one of claims 1-3, wherein the first Fc polypeptide comprises a first antigen-binding moiety and/or the second Fc polypeptide comprises a second antigen-binding moiety.
5. The heterodimeric protein of claim 4, wherein the first and/or second antigen-binding moiety comprises an antibody variable domain, an extracellular domain of a cell surface receptor, a soluble T cell receptor, or a ligand.
6. The heterodimeric protein of claim 5, wherein the first and/or second antigen-binding moiety comprises a VH, a VL, a VHH, a VH/VL pair, an scFv, a diabody, and/or a Fab.

7. The heterodimeric protein of claim 5, wherein the cell surface receptor is a tumor necrosis factor superfamily receptor, a vascular endothelial growth factor receptor, or a transforming growth factor receptor.
8. The heterodimeric protein of claim 5, wherein the ligand is a hormone or growth factor.
9. The heterodimeric protein of any one of claims 4-8, wherein the first and second antigen-binding moieties specifically bind to the same or different target molecules.
10. The heterodimeric protein of any one of claims 1-9, wherein the first and/or second Fc polypeptide comprises a CH1 domain, hinge region, CH2 domain and/or CH3 domain of human IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂.
11. The heterodimeric protein of claim 10, wherein the first and/or second Fc polypeptide comprises an antibody heavy chain.
12. The heterodimeric protein of claim 11, wherein the antibody heavy chain lacks a CH1 domain and/or a portion of a hinge region.
13. The heterodimeric protein of claim 11, wherein the antibody heavy chain is a full-length antibody heavy chain.
14. The heterodimeric protein of any one of claims 11-13, wherein the antibody heavy chain is a human IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, or IgA₂ heavy chain.
15. The heterodimeric protein of any of claims 11-14, wherein the first and/or second Fc polypeptide further comprises an antibody light chain.
16. The heterodimeric protein of claim 15, wherein the antibody light chain is a human kappa or lambda light chain.

17. The heterodimeric protein of any one of claims 1-6 and 9-14, wherein:
- a) the first Fc polypeptide comprises a first half-antibody comprising a first antibody heavy chain and a first antibody light chain; and/or
 - b) the second Fc polypeptide comprises a second half-antibody comprising a second antibody heavy chain and a second antibody light chain.
18. The heterodimeric protein of any one of claims 1-6 and 9-15, wherein:
- a) the first Fc polypeptide comprises a first half-antibody comprising a first antibody heavy chain and a first antibody light chain; and
 - b) the second Fc polypeptide comprises a second half-antibody comprising a second antibody heavy chain and a second antibody light chain.
19. The heterodimeric protein of claim 17 or 18, wherein the first and second half-antibodies bind to different target molecules or to different regions of the same target molecule.
20. The heterodimeric protein of any one of claims 1-11 and 13-19, wherein the first Fc polypeptide comprises an amino acid sequence that is at least 75% identical (optionally at least 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical) to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, 6-7, 10-11, 24-27, 48-51, and 62-65; and/or the second Fc polypeptide comprises an amino acid sequence that is at least 75% identical (optionally at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical) to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, 5, 12-13, 36-37, 60-61, and 66-67.
21. The heterodimeric protein of claim 20, wherein the first Fc polypeptide comprises an amino acid sequence that is at least 75% identical (optionally at least 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical) to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, 6-7, 10-11, 24-27, 48-51, and 62-65; and the second Fc polypeptide comprises an amino acid sequence that is at least 75% identical (optionally at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92,

93, 94, 95, 96, 97, 98, 99, or 100% identical) to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, 5, 12-13, 36-37, 60-61, and 66-67.

22. The heterodimeric protein of any one of claims 1-11 and 13-21, wherein the first Fc polypeptide and second Fc polypeptide comprise amino acid sequences that are at least 75% identical (optionally at least 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identical) to the amino acid sequences of SEQ ID NOs: 24 and 36; 24 and 37; 25 and 36; 25 and 37; 26 and 36; 26 and 37; 27 and 36; 27 and 37; 48 and 60; 48 and 61; 49 and 60; 49 and 61; 50 and 60; 50 and 61; 51 and 60; 51 and 61; 62 and 66; 62 and 67; 63 and 66; 63 and 67; 64 and 66; 64 and 67; 65 and 66; or 65 and 67, respectively.

23. The heterodimeric protein of any one of claims 1-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 51 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 61.

24. The heterodimeric protein of any one of claims 1-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 50 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 60.

25. The heterodimeric protein of any one any one of claims 1-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 51 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 60.

26. The heterodimeric protein of any one any one of claims 1-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 50 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 61.

27. The heterodimeric protein of any one of claims 2-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 49 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 61.

28. The heterodimeric protein of any one of claims 2-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 48 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 60.

29. The heterodimeric protein of any one any one of claims 2-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 49 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 60.

30. The heterodimeric protein of any one of claims 2-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 48 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 61.

31. The heterodimeric protein of any one of claims 1-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 65 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 67.

32. The heterodimeric protein of any one of claims 1-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 64 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 66.

33. The heterodimeric protein of any one of claims 1-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 65 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 66.

34. The heterodimeric protein of any one of claims 1-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 64 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 67.

35. The heterodimeric protein of any one of claims 2-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 63 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 67.

36. The heterodimeric protein of any one of claims 2-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 62 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 66.

37. The heterodimeric protein of any one of claims 2-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 63 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 66.

38. The heterodimeric protein of any one any one of claims 2-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 62 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 67.

39. The heterodimeric protein of any one of claims 1-11 and 13-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 27 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 37.

40. The heterodimeric protein of any one of claims 1-11 and 13-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 26 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 36.

41. The heterodimeric protein of any one of claims 1-11 and 13-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 27 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 36.

42. The heterodimeric protein of any one of claims 1-11 and 13-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 26 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 37.

43. The heterodimeric protein of any one of claims 2-11 and 13-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 25 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 37.
44. The heterodimeric protein of any one of claims 2-11 and 13-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 24 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 36.
45. The heterodimeric protein of any one of claims 2-11 and 13-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 25 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 36.
46. The heterodimeric protein of any one of claims 2-11 and 13-22, wherein the first Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 24 and the second Fc polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 37.
47. A pharmaceutical composition comprising the heterodimeric protein of any one of the preceding claims and a pharmaceutically acceptable carrier or excipient.
48. An isolated polynucleotide encoding the first and the second Fc polypeptides of the heterodimeric protein of any one of the preceding claims.
49. A vector comprising the polynucleotide of claim 48.
50. A recombinant host cell comprising:
- a) the polynucleotide of claim 48;
 - b) the vector of claim 49;
 - c) a first polynucleotide encoding the first Fc polypeptide of the heterodimeric protein of any one of the preceding claims, and a second polynucleotide encoding the second Fc polypeptide of the heterodimeric protein of any one of the preceding claims;

- d) a first vector comprising a first polynucleotide encoding the first Fc polypeptide of the heterodimeric protein of any one of the preceding claims, and a second vector comprising a second polynucleotide encoding the second Fc polypeptide of the heterodimeric protein of any one of the preceding claims;
 - e) a first polynucleotide encoding the first antibody heavy chain of the heterodimeric protein of claim 18, and a second polynucleotide encoding the second antibody heavy chain of the heterodimeric protein of claim 18, and optionally a third polynucleotide encoding the first antibody light chain of the heterodimeric protein of claim 18, and/or a fourth polynucleotide encoding the second antibody light chain of the heterodimeric protein of claim 18; or
 - f) a first vector comprising a first polynucleotide encoding the first antibody heavy chain of the heterodimeric protein of claim 18, and a second vector comprising a second polynucleotide encoding the second antibody heavy chain of the heterodimeric protein of claim 18, and optionally a third vector comprising a third polynucleotide encoding the first antibody light chain of the heterodimeric protein of claim 18, and/or a fourth vector comprising a fourth polynucleotide encoding the second antibody light chain of the heterodimeric protein of claim 18.
51. A method of producing a heterodimeric protein, the method comprising expressing in a cell:
- a) a first polynucleotide encoding the first Fc polypeptide of the heterodimeric protein of any one of claims 1-46; and
 - b) a second polynucleotide encoding the second Fc polypeptide of the heterodimeric protein of any one of claims 1-46,
- under conditions whereby the heterodimeric protein is produced.
52. A method of producing a heterodimeric protein, the method comprising expressing in a cell:
- a) a first polynucleotide encoding the first antibody heavy chain of the heterodimeric protein of claim 18;

- b) a second polynucleotide encoding the second antibody heavy chain of the heterodimeric protein of claim 18;
- c) a third polynucleotide encoding the first antibody light chain of the heterodimeric protein of claim 18; and
- d) a fourth polynucleotide encoding the second antibody light chain of the heterodimeric protein of claim 18,

under conditions whereby the heterodimeric protein is produced.

53. A method of producing a heterodimeric protein, the method comprising:

- a) expressing in a first cell a first polynucleotide encoding the first Fc polypeptide of the heterodimeric protein of any one of claims 1-46, under conditions whereby the first Fc polypeptide is produced;
- b) expressing in a second cell a second polynucleotide encoding the second Fc polypeptide of the heterodimeric protein of any one of claims 1-46, under conditions whereby the second Fc polypeptide is produced; and
- c) contacting the first and the second Fc polypeptides produced in steps (a) and (b), under conditions whereby the first Fc polypeptide and the second Fc polypeptide heterodimerize to produce the heterodimeric protein.

54. A method of producing a heterodimeric, the method comprising:

- a) expressing in a first cell a first polynucleotide encoding the first antibody heavy chain of the heterodimeric protein of claim 18 and second polynucleotide encoding the first antibody light chain of the heterodimeric protein of claim 18, under conditions whereby the first Fc polypeptide is produced;
- b) expressing in a second cell a third polynucleotide encoding the second antibody heavy chain of the heterodimeric protein of claim 18 and fourth polynucleotide encoding the second antibody light chain of the heterodimeric protein of claim 18, under conditions whereby the second Fc polypeptide is produced; and
- c) contacting the first and the second Fc polypeptides produced in steps (a) and (b), under conditions whereby the first Fc polypeptide and the second Fc polypeptide heterodimerize to produce the heterodimeric protein.

55. A method of producing a heterodimeric protein, the method comprising contacting the first Fc polypeptide and the second Fc polypeptide of the heterodimeric protein of any one claims 1-46 under conditions whereby the first Fc polypeptide and the second Fc polypeptide heterodimerize to produce the heterodimeric protein.

Figure 1




Figure 2A




Figure 2B




Figure 3

Target 1: Binding




Figure 4

Target 2: Binding




Figure 5 Target 1: Blocking





Figure 6



Target 1: SEA Assay

Figure 7A




Figure 7B




Figure 7C





Figure 7D



Target 1: SEA Assay

Figure 7E




Figure 7F




Figure 7G





Figure 7H



Target 1: SEA Assay

Figure 7I




Figure 7J




Figure 7K





Figure 7L



Target 1: SEA Assay

Figure 7M




Figure 7N




Figure 7O





Figure 7P



Target 2: SEA Assay

Figure 8A




Figure 8B




Figure 8C





Figure 8D



Target 2: SEA Assay

Figure 8E




Figure 8F




Figure 8G





Figure 8H



Target 2: SEA Assay

Figure 8I




Figure 8J




Figure 8K





Figure 8L



Target 2: SEA Assay

Figure 8M




Figure 8N




Figure 8O





Figure 8P



Target 2: SEA Assay

Figure 8Q




Figure 8R




Figure 8S





Figure 8T



Target 2: SEA Assay

Figure 8U




Figure 8V




Figure 8W




Figure 8X




Figure 9A




Figure 9B




Figure 10A




Figure 10B




Fig. 11A




Fig. 11C

anti-Target 1 heterodimeric protein binding to
FcγRIIIa F/F




Fig. 11E




Fig. 11F




Fig. 11G

anti-Target 1 heterodimeric protein binding to
FcγRIIIa F/F




Fig. 12A




Fig. 12B




Fig. 12D




Fig. 12E




Fig. 12F





Fig. 12G



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/53114

A. CLASSIFICATION OF SUBJECT MATTER

IPC - C07K 16/28 (2021.01)

CPC - C07K 16/28; C07K 16/283; C07K 2317/524; C07K 2317/526; C07K 2317/15

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2014/0079689 A1 (GENENTECH, INC.) 20 March 2014 (20.03.2014) abstract, para [0127], SEQ ID NOS: 1, 2.	1-3
A	CN110028584 A (BEIJING KEXIN BIOTECHNOLOGY CO., LTD.) 19 July 2019 (19.07.2019) SEQ ID NOS: 15, 16	1-3
A	US 2018/0118828 A1 (XENCOR, INC.) 3 May 2018 (03.05.2018) para [0161], [0185], [0192]	1, 2

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 January 2021

Date of mailing of the international search report

19 FEB 2021

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Lee Young

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/53114

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☐ forming part of the international application as filed:
 - ☐ in the form of an Annex C/ST.25 text file.
 - ☐ on paper or in the form of an image file.
 - b. ☐ furnished together with the international application under PCT Rule 13ter.1(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
 - c. ☒ furnished subsequent to the international filing date for the purposes of international search only:
 - ☒ in the form of an Annex C/ST.25 text file (Rule 13ter.1(a)).
 - ☐ on paper or in the form of an image file (Rule 13ter.1(b) and Administrative Instructions, Section 713).
2. ☒ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

3. Additional comments:

GenCore ver 6.4.1 SEQ ID NOs: 1, 2, 5, 6, 48, 50, 60 were searched.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 20/53114

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 4-55
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.